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ABSTRACT 
SUBCELLULAR LOCALIZATION OF HUMAN T-CELL LEUKEMIA 
VIRUS TYPE 1 TAX ONCOPROTEIN 
Kimberly Anne Fryrear 
Old Dominion University and Eastern Virginia Medical School, 2008 
Director: Dr. O. John Semmes 
Human T-cell Leukemia Virus Type 1 (HTLV-1) is a transforming retrovirus that 
gives rise to Adult T-cell Leukemia (ATL) and a variety of other subneoplastic 
conditions such as HTLV- Associated Myelopathy/ Tropical Spastic Paraperesis 
(HAM/TSP). In ATL, the transformation and immortalization of T-lymphocytes has 
been attributed to the expression and activity of a single HTLV-1 viral protein, namely 
the /rara-activating protein Tax. Although the exact mechanism of Tax-mediated 
transformation is uncertain, current studies support a model in which Tax induces 
genomic instability in the host cell through interference with DNA repair mechanisms, 
dysregulation of cell cycle progression, transcriptional activation of cellular genes, and 
protein-protein interactions with cellular partners leading to perturbation of their 
functions. Tax has both nuclear and cytoplasmic activities and shuttles between the two 
compartments via defined nuclear localization and nuclear export signals (NLS and NES, 
respectively), but the mechanisms regulating nucleocytoplasmic shuttling and targeting of 
Tax to distinct subcellular regions have yet to be determined. In this study we identified 
regions in Tax that regulate nucleocytoplasmic shuttling and dictate subnuclear targeting. 
We identified the region in Tax containing the sequence that targets the protein 
into discrete nuclear foci named Tax Speckled Structures (TSS). These TSS are protein 
complexes that partially overlap with the cellular marker of splicing SC35 and contain 
other cellular proteins such as DNA-PKcs and Chk2. Targeting Tax to TSS places Tax in 
a centralized location to affect transcription, DNA damage recognition and other 
processes, and targeting to these foci is therefore crucial to Tax-mediated transformation. 
We identified the Tax speckle targeting signal (TSTS) as the Tax region containing 
amino acids 50-75. This sequence lies downstream from the Tax NLS and is completely 
separable from the NLS. We demonstrated that a mutant missing the NLS and a mutant 
missing the TSTS can interact with each other and rescue proper localization through 
complementation of the deleted domains. 
We also determined that dimerization of Tax is required for nuclear localization. 
The previously defined Tax dimerization domain spans 150 amino acids which represent 
nearly one-half of the protein. Within this larger domain are three subdomains that were 
identified as regions required for Tax dimerization. We created Tax mutants deleted in 
individual dimerization subdomains and assayed their ability to dimerize and their 
subsequent subcellular localization. Tax mutants deleted in one of the three dimerization 
subdomains were unable to efficiently homodimerize and were retained in the cytoplasm. 
They were able to weakly dimerize with wildtype Tax which resulted in partial rescue of 
nuclear localization. A mutant deleted in two dimerization subdomains was unable to 
dimerize with itself or with wildtype Tax and remained in the cytoplasm. A Tax mutant 
that was induced to become a dimer was subsequently able to translocate into the 
nucleus. 
Our studies further identified that cellular proteins including the ubiquitin ligase 
RNF4 affect the subcellular localization of Tax. Previous studies suggested that 
ubiquitylation of Tax is associated with its cytoplasmic localization, but the specific 
ubiquitin ligase involved had not been identified. We demonstrated that RNF4 was able 
to ubiquitylate Tax in vitro. This study is the first to identify a substrate protein for the 
ubiquitylation activity of RNF4. Overexpression of RNF4 led to an egress of Tax from 
the TSS and the nucleus. We co-purified Tax and RNF4 from transfected cell lystates and 
demonstrated that they are both present in a protein complex. Increasing RNF4 
expression increased the cytoplasmic activity of Tax and decreased the nuclear activity of 
Tax in a dose-dependent manner, suggesting that RNF4's ubiquitylation of Tax affects its 
subcellular localization and subsequently affects Tax function. 
Overall, in this study we have identified novel domains and interactions that 
contribute to the regulation of the subcellular localization of Tax. The knowledge gained 
through this work will provide a better understanding of Tax function and its role in 
cellular transformation. 
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Human T-Cell Leukemia Virus Type 1 
Human T-cell Leukemia Virus-1 (HTLV-1) is an oncogenic retrovirus that is 
etiologically linked to both an aggressive malignancy of CD4+ lymphocytes, namely 
adult T-cell leukemia (ATL), and a neurodegenerative disease known as HTLV-
Associated Myelopathy/Tropical Spastic Paraperesis (HAM/TSP) as well as several other 
subneoplastic conditions (1-4). HTLV-1 was the first discovered human retrovirus and 
was the first retrovirus to be linked to a human cancer (1). Retroviruses in general 
consist of a two-stranded positive sense RNA viral genome that is embedded in a 
nucleocapsid and packaged into enveloped virions. Retroviruses are subdivided into two 
classes: simple and complex. Simple retroviruses have only gag, pro, pol, and env genes 
while complex retroviruses also contain nonstructural regulatory genes. 
HTLV-1 is a member of the Deltaretrovirus genera of the Orthoretrovirinae 
family (5). The genome for HTLV-1 is 9 kilobases in length and contains gag, pol, pro, 
and env genes along with 5' and 3' long terminal repeats (LTRs). The gag gene encodes 
for the capsid, nucleocapsid, and matrix proteins. The pol gene encodes the reverse 
transcriptase needed to reverse transcribe the RNA viral genome into DNA to be 
integrated into the host genome (6). The pro gene encodes for the viral protease that 
cleaves the products of the gag gene during maturation of the virion. The env gene 
encodes for the surface glycoprotein (SU) and the transmembrane protein (TM) that make 
This dissertation follows the format of The Journal of Biological Chemistry. 
up the viral envelope proteins (7). The long terminal repeats contain signals that regulate 
the transcription and expression of the viral genes. 
In addition to the gag, pol,pro and env genes and the long terminal repeats 
(LTRs) that are common to most retroviruses, HTLV-1 contains a region at its 3' 
terminus designated as pX (8-10). At the time of the discovery of HTLV-1, this pX 
region gave the HTLV-1 viral genome a unique structure from other known animal 
retroviruses. This led to the establishment of a new retroviral group which now includes 
HTLV-2, HTLV-3, HTLV-4, Bovine Leukemia Virus (BLV), Primate T-Lymphotropic 
Virus (PTLV), and Simian T-cell Leukemia Virus (STLV) (11). Unlike other retroviruses 
that rely on cellular proteins for regulation, HTLV-1 can regulate itself through proteins 
encoded within the pX region. This pX region contains multiple overlapping ORFs which 
are responsible for encoding nonstructural accessory and regulatory genes such as tax, 
rex, p27!, pll1, pSC^1, pl3n, and HBZ genes (9,12). The Tax and Rex proteins are two 
essential positive regulators of viral transcription required for viral replication. Rex is a 
27 kDa RNA-binding protein that aids in the export of unspliced (gag/pro/pol) and singly 
spliced (env) mRNAs over doubly spliced mRNAs from the nucleus (13). A primary 
function of Tax is to potently activate viral transcription by recruiting cellular 
transcription factors to the viral LTR (9). Tax has, however, many other functions within 
the host cell which promote cellular transformation and will be later discussed in detail. 
The accessory proteins are not required for replication, but may be necessary for 
persistent infection and immune response evasion (12). 
Replication of HTLV-1 follows that of all retroviruses (6). The retroviral life 
cycle begins with infection of the host cell. The enveloped retroviral virion binds to a 
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receptor on the surface of the host cell and enters the host cell by fusion of the viral 
envelope and plasma membrane (14). After the viral core has entered the host cell, the 
two-stranded positive sense RNA viral genome is reverse transcribed into double-
stranded RNA/DNA hybrids by the viral enzyme reverse transcriptase. The RNA 
template is then degraded and the reverse transcriptase copies the single-stranded DNA 
into double stranded DNA during multiple steps. This provirus and additional viral 
proteins are transported into the nucleus, and the provirus is integrated into the host cell 
genome by the viral integrase at random sites (15). Viral genes are transcribed by host 
cell transcription machinery, and multiply spliced viral mRNAs, such as that of the 
regulatory proteins Tax and Rex, are transported to the cytoplasm. The expression of 
these regulatory proteins allows for the export of the singly and unspliced viral mRNAs. 
The differentially spliced mRNAs are translated into virion structural proteins and 
enzymes while the unspliced mRNAs become the viral RNA genomes for the newly 
developing virions. The virion proteins and viral genome are assembled in the cytoplasm, 
and the new virions are released by budding from the host cell. Capsid proteins are 
proteolytically processed within the new virions to become mature, infectious virus (6). 
In the case of HTLV-1 infection, the production of virions can only be seen when 
infected cells or tissues are cultured in vitro (14,16). HTLV-1 can infect CD4+ and 
CD8+ T-cells, B cells, and synovial cells, but only CD4+ T-cells are transformed and 
undergo clonal expansion to become ATL (17,18). The virus binds to the T-cells via the 
GLUT-1 glucose transporter, a cellular receptor present on nearly all mammalian cells 
(7,19,20). Binding between the viral Env and GLUT-1 allows for fusion of the cell and 
virus followed by viral entry. Transmission and persistence of HTLV-1 in vivo is 
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believed to occur via the exchange of infected T-cells and cell-to-cell contact infection 
rather than through production and transmission of infectious virions due to the low 
infectivity of HTLV-1 virions (14,16). Unlike HIV which relies on virions for infection 
of host cells, HTLV-1-infected T-cells can form syncytia with uninfected cells or may 
simply pass the viral genome and viral Gag protein from cell-to-cell via a reorganization 
of the cytoskeleton to form a "virological synapse" (21). The use of cell-to-cell 
transmission and clonal expansion of infected T-cells may allow HTLV-1 to spread 
without detection by the immune system. 
Epidemiology of HTLV-1 
It is estimated that globally there are currently 20-30 million people infected with 
HTLV-1 (22-24). The geographic distribution of HTLV-1 includes high prevalence in 
South America, Africa, southwestern Japan, and the Caribbean Islands with isolated 
pockets of infection occurring in Iran and Melanesia (9,25-30). In the Caribbean, it is 
estimated that 3-4% of the population is seropositive for HTLV-1 (31). In Japan, more 
than 1.2 million people are believed to be infected (9,32). In the United States, HTLV-1 
infection seems to prevalent only in specific high risk groups including immigrants from 
endemic areas and their spouses, intravenous drug users and those involved in 
prostitution (22,31). Studies of the international prevalence of HTLV-1 infection, 
however, may be somewhat skewed due to the limited composition of the studied 
populations, the early use of enzyme-linked immunoassays (EIAs) with reduced-
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specificity, and serologic assays that did not discriminate between HTLV-1 and HTLV-2 
(22). 
There are five different published subtypes of HTLV-1 including subtype A, also 
known as the cosmopolitan subtype, subtype B, subtype C, subtype D, and subtype E. 
These subtypes are based on differences in the pro viral DNA sequence of the env gene 
and/or long terminal repeat region (33). Subtype A is the most studied and most widely 
distributed subtype and includes the sequence originally identified for HTLV-1 in Japan 
(34). Subtypes B, D, and F are found in Central Africa, and subtype E is found in South 
and Central Africa (33). Subtype C seems to have its origins and highest prevalence in 
Melanesia (35). Although the subtypes of HTLV-1 seem to be linked geographically, 
there has been no link observed between infection with a specific HTLV-1 subtype and 
development of either ATL or HAM/TSP (36,37). 
Transmission of the virus occurs through sexual intercourse, sharing of needles 
and syringes during intravenous drug use, transfusion of infected blood products, and 
vertical transmission from mother to child during breastfeeding (28,31). Anti-HTLV-1 
antibodies and proviral DNA sequences have both been detected in saliva suggesting that 
the virus could possibly be spread through contact with saliva, but there have been no 
reported cases of transmission by this route (38). HTLV-1 is believed to spread between 
hosts through the transmission of infected T-lymphocytes. Both breast milk and seminal 
fluid are rich stores of T-lymphocytes, and there is some evidence that seminal fluid 
enhances HTLV-1 replication through TGFP-mediated upregulation of viral transcription 
(39). Transmission may occur during cell-to-cell contact on mucosal surfaces of the 
mouth during breastfeeding and the vagina or penis during intercourse, and transmission 
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rates may be enhanced by any sort of lesions or ulcerations of the mucosa (16). Blood 
transfusions or sharing of infected needles by intravenous drug users would allow direct 
transfer of infected T cells into the bloodstream of the new host. For this reason, the Food 
and Drug Administration (FDA) began recommending screening of all blood donations in 
the United States for HTLV-1 in 1988, and since then similar screening protocols have 
been established in Europe, Canada, Japan, and Brazil (22). 
Following the initial HTLV-1 infection, infected T-cells may travel by means of 
the bloodstream or lymphatic vessels throughout the body to establish reservoirs of 
infection in areas like the skin, thymus, liver, spleen, lymphoid tissues, and perivascular 
regions in the central nervous system (16). The specific location of these reservoirs of 
infection may contribute to the development of specific HTLV-1 associated diseases and 
conditions. 
Diseases of HTLV-1 Infection 
Infection with HTLV-1 can lead to adult T-cell leukemia (ATL), HTLV-1 
associated myelopathy/tropical spastic paraparesis (HAM/TSP), uveitis, mycosis 
fungoides, and infective dermatitis. In addition, there are a number of other conditions 
that appear to be related to HTLV-1 infection including arthritis, pneumonitis, urinary 
tract disorders, and susceptibility to other infections, but additional studies must be 
completed to confirm these associations with HTLV-1 (22). 
HTLV-1 infected individuals possess a 5% lifetime risk of developing either 
Adult T-cell Leukemia or HAM/TSP. These two conditions are most often mutually 
exclusive, although there have been a few reported cases of presentation of both 
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HAM/TSP and ATL in the same patients (40-43). The criteria for determining which 
infected individuals will develop each condition remain unknown. Infection by vertical 
transmission through breastfeeding during childhood may increase the likelihood of 
developing ATL, while ATL cases following infection post-transfusion are very rare (44-
47). This may be due in part to establishment of a reservoir of infection in the thymus 
early in life, and the subsequent infection of mature and immature thymocytes leading to 
development of ATL in later decades (16). Development of HAM/TSP seems to be 
linked to infection later in life through blood transfusion, intravenous drug use or sexual 
intercourse (22), but there are still no definitive answers as to why only a small 
percentage of infected individuals develop either of these two diseases. 
Adult T-cell Leukemia/Lymphoma 
Adult T-cell leukemia was the first cancer causally linked to a human retrovirus. 
In 1977 in Japan, Uchiyama et al described a leukemia with a unique morphology 
consisting of lobulated nuclei that they termed Adult T-cell leukemia (ATL) (48). In the 
United States in 1980, Poiesz et al described the isolation of a new retrovirus from a cell 
line derived from a patient with cutaneous T-cell lymphoma which they named Human 
T-cell Leukemia Virus (HTLV) (1). During continued research in Japan, two groups 
detected unique serum antibodies in ATL patients and eventually isolated a retrovirus that 
was named Adult T-cell Leukemia Virus (ATLV) (49,50). Subsequent studies led to the 
realization that the virus identified in the US and the virus identified in Japan were 
actually the same virus, and the decision was made to refer to the virus as Human T-cell 
Leukemia Virus Type 1 (HTLV-1) and the disease caused by the virus as Adult T-cell 
leukemia (ATL) (51). 
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Adult T-cell Leukemia is a lymphoproliferative T-cell malignancy that occurs in 
1-5% of infected individuals after a long latent period of 20-30 years (22,52,53). Several 
different patterns of symptoms characterize the disorder, and therefore ATL is 
categorized into four forms: acute, chronic, smoldering, and lymphoma-type (6). Some 
patients develop a pre-ATL syndrome characterized by an elevated number of circulating 
white blood cells prior to the onset of symptoms. These individuals have abnormal 
lymphocytes that arise from a few HTLV-infected cells (54,55). The chronic or 
smoldering forms of ATL are characterized by low levels of circulating lymphoid cells 
and skin lesions caused by infiltration of leukemic cells (56,57). Some patients with 
chronic or smoldering ATL and some with pre-ATL progress to acute ATL. 
Acute ATL is characterized by greatly elevated numbers of circulating CD4+ 
malignant T- cells that arise from clonal expansion of cells that contain small numbers of 
integrated HTLV proviruses (2,10,49,58,59). These cells have a distinct morphology with 
multilobulated, convoluted nuclei and are also referred to as "flower cells" (48,56,60,61). 
Acute ATL patients often display skin lesions and have enlarged lymph nodes, liver, and 
spleen, and may exhibit hypercalcemia due to lysis of bone tissue (56,59,62-64). 
Lymphoma-type patients develop clonal T-cell lymphomas that contain integrated HTLV 
provirus (2,57,65). Between 50-75% of ATL cases are classified as acute or lymphoma-
type, and about 25% are either chronic or smoldering (22,66). With no treatment, acute 
ATL is invariably and rapidly fatal, and current conventional chemotherapies are 
ineffective against acute ATL (22). Current studies of novel treatments such as 
interferon-a plus zidovudine, HDAC inhibitors, monoclonal antibodies, and allosteric 
stem cell transplantation have had limited successes, but none have been shown to 
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provide substantial improvement over chemotherapy (64). Patients with HTLV-1 -
associated lymphomas have a life expectancy of approximately 10 months; those with 
acute ATL have an average life expectancy of only 6 months with the usual causes of 
death being pulmonary complications, opportunistic infections, and sepsis (65,67,68). 
HTLV-1 AssociatedMyelopathy/Tropica! Spastic Paraparesis 
HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is a 
progressive neurodegenerative disorder characterized by slow-onset spastic paraparesis 
accompanied by sphincter, proprioceptive, and sensory dysfunction (22). The disease 
develops from severe white matter degeneration and fibrosis resulting from the 
immunological response to HTLV-1 infection and parenchymal infiltration of 
mononuclear cells into the gray and white matter of the thoracic spinal cord (69). The 
disease is most often diagnosed in adults, and develops more frequently in women than in 
men (70). Evidence suggests that adult exposure to HTLV-1 through blood transfusion or 
sexual transmission of HTLV-1 predominantly leads to HAM/TSP rather than ATL 
(71,72). Current therapies for HAM/TSP include corticosteroids, immunosuppressive 
drugs, anti-spasmodics, and physical therapy, but for HAM/TSP patients, current 
treatments offer unsatisfactory results with huge costs both financially and in quality of 
life (22). 
Uveitis and Other HTL V-l Associated Conditions 
There have been several other conditions with a suggested link to HTLV-1 
infection. Rheumatologic conditions including polymyositis, brachioalveolar 
pneumonitis, uveitis, auto-immune thyroiditis and arthritis have all been associated with 
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viral genome or viral proteins detected in affected tissues, but only uveitis, mycosis 
fungoides, and infective dermatitis have enough epidemiologic evidence to support a 
causative role for HTLV-1 (16). In studies of HTLV-assiciated uveitis, researchers found 
a higher number of HTLV-1 infected T-lymphocytes within the vitreous fluid when 
compared to the peripheral blood compartment (73). Higher rates of arthritis were 
associated with HTLV-seropositive patients than seronegative ones in an epidemiologic 
study by Murphy et al (74), and high proviral load in peripheral blood and synovial 
compartments has been associated with rheumatoid arthritis in HTLV-1-infected patients 
(75), but more studies are needed to strengthen the link between these conditions and 
HTLV-1 infection. 
Prevention 
There have been several attempts to develop a vaccine against HTLV-1 infection. 
In a study by Shida et al, the env gene from HTLV-1 was cloned into the vaccinia virus 
with the hemagglutin (HA) gene to form a live recombinant virus. This virus induced 
antibody production in rabbits with some protection against HTLV-1 infection (76). 
Kataoka et al were able to demonstrate passive immunization with HTLV-1 immune 
serum in rabbits (77). More recently, a multivalent peptide CTL vaccine with three 
HTLV-1 Tax protein peptides was developed by Sundaram et al that elicited cellular 
responses in transgenic mice and mice infected with an HTLV-1 Tax recombinant 
vaccinia virus (78,79). This same group tested the immunogenicity of antibodies against 
the gp21 and gp46 subunits of the envelope glycoprotein of HTLV-1 that were able to 
prevent virus-induced syncytia formation (80). Despite these successes however, there 
are currently no HTLV-1 vaccines being tested in clinical trials. 
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Due to the lack of an effective vaccine against HTLV-1 infection, currently the 
best means of prevention of infection is education. At risk groups such as sex workers, 
intravenous drug users, and women in endemic areas need to be educated in the 
importance of safe sex practices, eliminating needle-sharing, and avoidance of 
breastfeeding by infected mothers. Health organizations need to implement these 
programs in addition to regular screening of all blood donations in order to prevent 
transmission of the virus through transfusions. 
HTLV-1 OncoproteinTax 
In ATL, the transformation of CD4+ lymphocytes is mediated through the 
expression of the HTLV-1 /rajis-activating protein, Tax. The link between Tax 
expression and transformation has been well established through both in vivo and in vitro 
experiments. Introduction of tax into NIH 3T3 and Rat-1 cells resulted in transformation, 
and those cells became tumorigenic when injected into nude mice (81). Transfection of a 
Tax-expressing vector was shown to immortalize human T-lymphocytes, and tax 
transgenic mice exhibited neurofibromas, mesenchymal tumors and lymphomas (81-84). 
Tax is a 353 amino acid protein primarily encoded by a region near the 3' LTR of 
the viral genome designated as the pX region. Tax is predominantly nuclear but has 
pleiotropic functions requiring that it shuttle between the nuclear and cytoplasmic 
compartments (85). Tax is phosphorylated on several serine and threonine residues, and 
our laboratory and others have found that this phosphorylation differentiates the "active" 
and "inactive" forms of Tax (86-88). Others laboratories have shown that Tax can be 
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both ubiquitinated and sumoylated, and these modifications contribute to the regulation 
of Tax subcellular localization (89,90). 
The pleiotropic activities of Tax require it to interact with many different cellular 
proteins, and, as such, Tax has many previously identified functional domains. These 
include a nuclear localization signal (91,92), a nuclear export signal (85,93), a cyclic-
AMP response element binding (CREB) interaction domain, p300/CBP binding domain, 
NF-KB binding domain (94-98), a zinc-finger domain (99), a dimerization domain (100-
102), a PDZ-binding domain (103,104), a KlX-interacting domain (95,105), a leucine 
zipper-like domain (97), and an activation specific region (106). Additional motifs in 
Tax that may be involved in protein-protein interactions include an SH3 domain, a LIM 
domain, and a coiled-coil structure that would all expand the possible cellular binding 
partners of Tax (107). The exact mechanism of Tax-mediated transformation is 
unknown, but studies indicate that transformation is related to the ability of Tax to 
deregulate transcription of genes and signaling pathways involved in cellular 
proliferation, cell cycle control, DNA repair, and apoptosis. 
Transcriptional Trans-activation by Tax 
A primary function of Tax is to potently enhance transcription of viral genes. Tax 
has limited direct contact with DNA through a region in amino acids 89-110, but 
activates transcription through recruitment of cellular transcription factors to the viral 
LTR (108,109). The HTLV-1 LTR contains three highly conserved 21-bp repeat 
elements commonly referred to as the Tax-responsive elements (TRE) which are critical 
to Tax-mediated transcriptional activation (108). Each TRE has three regions, A, B, C, 
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and the center B region of the TRE has a conserved 8-nucleotide core sequence 
TGACGG(T/A)(C/G)(T/A) that closely resembles a consensus cAMP responsive element 
(CRE) (110). Tax recruits the cyclic-AMP responsive element binding protein (CREB) to 
the viral LTR and stabilizes the complex on the viral promoter via a domain in the N-
terminus of Tax (111,112). The recruitment of CREB by Tax to the LTR provides a high-
affinity binding site for transcriptional coactivators such as CREB binding protein (CBP), 
p300, and p300/CBP-associated factor (P/CAF) (111,113-116). These coactivators 
induce histone acetylation and chromatin remodeling to allow for an even more stable 
transcription complex at the promoter (107,115). Studies have shown that Tax can also 
recruit the coactivator CBP in the absence of CREB phosphorylation resulting in viral 
transcription (117,118). 
Just as Tax activates transcription of the viral genes by recruiting cellular 
transcription factors to the viral LTR, Tax also /rafts-activates and /raw-represses 
transcription of cellular genes through interactions with cellular transcription factors 
including CREB/ATF, AP-1, SRF, NF-KB and NFAT (119,120). Cellular genes with 
cAMP responsive elements can be trans-activated by Tax in the same manner as the viral 
LTR (113). Tax can also recruit other CREB/activating transcription factor (CREB/ATF) 
family members to CRE promoters to activate transcription (114). 
Tax activates the NF-KB pathway through interactions with proteins in both the 
nucleus and the cytoplasm. The NF-KB family members are usually sequestered in an 
inactive form in the cytoplasm by inhibitory proteins such as IKBOI and IKBP (121,122). 
Tax activates transcription via the canonical NF-KB pathway by directly binding to IKB 
kinase y/NF-KB essential modulator (IKKy /NEMO), leading to phosphorylation and 
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degradation of IKB and release of NF-KB to translocate into the nucleus to activate 
transcription (96,123-125). Tax can also activate the noncanonical NF-KB pathway by 
interacting with IKKy and pi 00, the precursor for p52 resulting in the processing of pi 00 
into p52 and its release to the nucleus to activate transcription (124). In the nucleus, Tax 
can physically bind to p50, p65, c-Rel, and NF-KB-2 to stabilize these factors on NF-KB-
responsive promoters (124). The result of Tax expression is the constitutive activation of 
the NF-KB pathway in HTLV-1-infected cells leading to upregulation of expression of 
genes involved with processes such as proliferation and evasion of apoptosis. 
Tax is also able to interact directly with the serum response factor (SRF) and its 
cofactor, ternary complex factor (TCF) to activate or repress transcription at promoters 
with serum response elements (SREs) (119,126,127). This pathway is responsible for 
transcription of proto-oncogenes c-Fos, c-Jun, JunB, JunD, and Fra-1 which regulate 
expression of AP-1 responsive genes involved in evasion of apoptosis and cellular 
proliferation (8). 
Through the interactions with these pathways Tax can cause major changes in the 
expression of hundreds of genes (119,128). In addition, Tax can physically interact with 
many cellular proteins and thereby activate or repress their functions (129-143). The 
downstream effects of Tax transcriptional activation of cellular genes and direct protein-
protein interactions is manipulation of the cell cycle, accumulation of mutations due to 
interference with DNA repair, and evasion of apoptosis. 
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Tax-mediated Dysregulation of Cell Cycle 
The cell cycle involves defined stages during which the cell doubles its number of 
organelles and volume of cytoplasm, duplicates DNA, segregates the DNA to opposite 
ends of the cell and then separates into two daughter cells (6). Theses stages are named 
the gap, or G phases (Gl, G2, GO), the synthesis phase (S), and the mitotic phase (M). 
During Gl phase, the cell prepares for DNA replication by producing synthetic enzymes. 
Gl phase is followed by S phase during which chromosomes are duplicated. This is 
followed by G2 phase when the cell prepares for division which occurs during the M 
phase. The cell will then either return to the Gl phase or enter a quiescent state known as 
GO phase (6). The progression of the cell cycle from one phase to the next is regulated by 
the phosphorylation state of proteins called cyclins that are phosphoryalated by cyclin 
dependent kinases (cdks) (144). Specific cyclin/cdk complexes regulate each phase of the 
cell cycle. Progress through the cell cycle is also governed by molecular checkpoints 
involving cdk inhibitors that can prevent the continuation of the cell cycle at specific 
phases (145). 
Tax interacts with several cell cycle regulatory proteins resulting in accelerated 
progression past crucial checkpoints. In the Gl phase of the cell cycle, Tax 
transcriptionally upregulates the expression of several cyclins and cyclin-dependent 
kinases (cdks) including cyclin D2, cdk4, cdk2, and cyclin E (135,146), and Tax binds to 
cyclin D3, cyclin D2, and cdk4 and functions to stabilize cyclin D/cdk4 complexes (133). 
When the concentration of cyclin D/cdk complexes increases, the cell reaches what is 
known as the restriction point and is committed to completing the Gl phase of the cell 
cycle (144). Tax transcriptionally represses and/or physically represses cell cycle 
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inhibitors that would prevent passage throught the restriction point (132,145). Tax also 
activates transcription of E2F and alters the Rb-bound and Rb-unbound ratio of E2F 
(144). Together these events result in an abundance of activated cyclin D/cdk complexes 
and accelerated Rb phosphorylation and subsequent E2F release accelerating the cell 
through the Gl phase towards the Gl/S checkpoint. 
Tax expression abrogates the p53-mediated Gj/S checkpoint and dysregulates S 
phase. During the transition from Gl to S phase, the cell must pause to repair DNA 
damage before DNA replication to prevent fixing the errors in daughter cells (144). This 
Gl/S checkpoint is regulated by p53. Tax stabilizes p53 and in doing so functionally 
inactivates p53 (147). Using an additional p53-independent transcriptional upregulation 
of p21wafl and repression of cyclin A, Tax represses the checkpoint cyclin A/cdk2 
complex and promotes cyclin D/cdk2 complex formation and progression through the 
Gl/S checkpoint (130,148-152). Tax repression of cyclin A prevents cyclin A/cdk2-
mediated phosphorylation of pre-replication complexes and may also allow for redundant 
DNA replication during S phase (151). The decreased expression of cyclin A due to Tax-
mediated repression may cause an acceleration of mitosis and contribute to the failure of 
mitotic checkpoint activation (151,153). 
The G2/M checkpoint is the last chance for the cell to repair damaged DNA prior 
to mitosis. DNA damage is recognized by the recognition machinery regulated by 
ATM/ATR signaling pathways and activates the G2/M checkpoint through Chkl and 
Chk2 (144). Tax interacts with both Chkl and Chk2 and dysregulates the G2/M 
checkpoint (138). Our lab observed that Tax binds to Chk2 resulting in its activation and 
an accumulation of cells in G2/M that was relieved by caffeine, indicating that the 
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accumulation was due to G2 checkpoint activation rather than M checkpoint activation 
since caffeine inhibits ATM/ATR kinases (129,134). Conversely, Park et al have found 
that Tax physically interacts with Chkl and impairs phosphorylation of p53 by Chkl. 
They also found that Tax was able to block degradation of cdc25A and attenuate G2 
arrest caused by activation of Chkl following y-radiation (IR) (142). Additionally, Tax 
impairs mitosis by directly binding to the mitotic spindle proteins, mitotic arrest defective 
protein 1 and 2 (MADs), affecting their stability, localization, and functions and 
preventing checkpoint activation (136),(154). Tax interacts with APCcdc20 prematurely 
degrading securin and resulting in defective cytokinesis and improper chromatid 
separation leading to aneuploidy (139). 
Overall the effects of Tax on the cell cycle lead to accelerated progression 
through Gl and S with inactivation of Gl/S checkpoint and subsequent loss of DNA 
damage repair. Tax causes improper replication of DNA during S phase which may result 
in duplicated chromosomes. Tax abrogates S and G2 checkpoints which increases the 
likelihood of DNA damage becoming fixed in daughter cells.Tax-induced loss of mitotic 
checkpoints and premature degradation of regulatory proteins result in mistakes in 
chromosome separation during mitosis. The end result is genomic instability and 
eventual cellular transformation. 
Tax-mediated Dysregulation of DNA Repair 
Tax-expressing cells display a variety of chromosomal abnormalities including 
deletions, translocations, rearrangements, duplications, micronuclei formation and 
aneuploidy (81,155-158). During normal progression through the cell cycle, errors occur 
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during DNA replication. Generally, the cellular repair process is sufficient for correcting 
these errors. Critical to this response are checkpoints in the cell cycle that pause 
progression to allow time for DNA damage repair to occur prior to permanent 
establishment of these errors in daughter cells following mitosis. As described above, Tax 
can abrogate these checkpoints during the cell cycle that decrease time for DNA repair, 
but Tax can also directly inhibit DNA repair by interfering with the chromosome 
maintenance and DNA repair pathways. 
DNA is repaired using several pathways including base excision repair, 
nucleotide excision repair, and double-strand break repair (159). There is evidence that 
base excision repair activity is specifically repressed by Tax (159) partly by repressing 
transcription of human DNA polymerase p (160). This enzyme is involved in both base 
excision repair and mismatch repair, and suggests that Tax may also inhibit mismatch 
repair (MMR), although additional studies are needed to confirm inhibition of MMR by 
Tax (144). Tax may impair nucleotide excision repair by trans-activating transcription of 
proliferating cell nuclear antigen (PCNA) (156). Increased PCNA has been shown to 
promote DNA replication by DNA polymerase 8 through damaged regions of template 
DNA, thus inhibiting nucleotide excision repair of those regions (161,162). Damage 
resulting in double-strand breaks (DSB) typically requires repair via the error-prone non-
homologous end joining (NHEJ) pathway. This pathway recognizes DSBs, processes the 
ends by deleting 1-10 bases, and joins the two broken ends (163). By microarray 
analysis, Tax-expressing cells were found to have decreased expression of two important 
members of this pathway, Ku and DNA-PKcs (164). The induction of micronuclei is a 
sensitive measurement of mitogen-induced DNA damage (165). Majone et al found that 
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Tax increases mitogen-induced micronuclei formation and that Tax-induced micronuclei 
formation is dependent on Ku80 (166,167). Our lab has shown that Tax binds to and 
functionally impairs DNA-PK as well as the downstream DNA-PK target checkpoint 
protein Chk2 and early damage response gene 53BP1 (134,168). DNA-PK is also 
involved in the maintenance of telomeric ends to prevent them from being recognized as 
DSBs (169). Tax represses expression of another enzyme involved in telomere 
maintenance, human telomerase (hTert) (170). Together the repression of hTert and 
inhibition of DNA-PKcs by Tax may result in telomeres being treated as DSBs which 
results in translocations, chromosome breaks, and chromosomal end-to-end fusion 
leading to aneuploidy. The overall repression of DNA repair by Tax is thought to 
contribute to an accumulation of mutations resulting in genomic instability and eventual 
cellular transformation. 
Tax-mediated Dysregulation ofApoptosis 
Cells with significant DNA damage are usually induced to undergo apoptosis. 
Tax-expressing cells are resistant to apoptotic signals (171). This resistance has been 
found to be mediated through the trans-repvession by Tax of apoptotic genes, trans-
activation by Tax of anti-apoptotic genes and constitutive activation by Tax of the NF-KB 
pathway all of which have been described previously. Another means of dysregulation of 
apoptosis by Tax involves interference with the function of p53. DNA damage leads to 
activation of p53 resulting in cell cycle arrest or apoptosis (172). Moderate damage can 
usually be repaired during the pausing of the cell cycle at the p53-mediated Gl/M 
checkpoint, but extensive damage causes p53 to trigger apoptosis through upregulating 
pro-apoptotic genes and activating caspase cascades (172). Tax has been shown to 
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inactivate the function of p53, although the exact mechanism of the inactivation is poorly 
understood (147,173,174). Some studies indicate that Tax may compete with p53 for 
binding to p300/CBP (175). Other studies suggest that inactivation of p53 by Tax 
involves the NF-KB/RelA pathway (174). Tax also inhibits apoptosis through activation 
of AKT and the subsequent expression of the anti-apoptotic gene BCL-xl (176). This tips 
the balance between the pro- and anti-apoptotic Bel proteins towards survival and 
resistance to apoptosis. The functions of Tax which dysregulate cell cycle, DNA repair, 
and apoptosis result in an accumulation of mutations and chromosomal aberrations that 
are characteristic of genomic instability and lead to cellular transformation. 
Tax Cellular Localization 
All of these deleterious effects can be ascribed to protein-protein interactions 
between Tax and cellular proteins. In order for Tax to accomplish these interactions, it is 
necessary that cellular nuclear proteins be brought into close proximity of Tax. One way 
to accomplish this is through the targeting of Tax to some of the protein complexes that 
exist within discrete locations within the nucleus. These complexes of subnuclear protein 
structures assemble at specific subnuclear sites to perform specific functions (177). 
Categories of proteins believed to form these subnuclear structures are transcription 
factors, small nuclear ribonucleorprotein particles (snRNPs), chromatin remodeling 
proteins, and DNA damage recognition and repair proteins (177). 
There are several known types of large protein complexes present in the nucleus 
including speckles, paraspeckles, Cajal bodies, gems, and Nuclear Domain 10 (ND10)/ 
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promelocytic leukemia (PML) bodies (178,179). Nearly all of these subnuclear 
structures contain subpopulations of cellular splicing factors, but each is distinguished by 
the presence of a nuclear protein unique to each structure (180). Cajal Bodies contain 
snRNPs for pre-messenger RNA and ribosomal RNA processing and the autoantigen p80 
coilin (180). Gems, or Gemini of Cajal bodies, contain the "survival of motor neurons" 
protein, SMN (181). ND10/PML bodies contain promyelocytic leukemia protein (182). 
Paraspeckles contain paraspeckle proteins 1 and 2 and p54/nrb (180). Nuclear Speckles 
are interchromatin granule clusters (IGCs) that contain the pre-messenger RNA splicing 
machinery including snRNPs, non-snRNP splicing factors, and spliceosome subunits 
such as the spliceosome component 35 protein (SC35) (180). These speckles are also 
referred to as SC35 domains. 
Nuclear Tax localizes to discrete nuclear bodies that we previously named Tax 
Speckled Structures (TSS) (183). These foci are IGCs located at sites partially 
overlapping with transcriptional hot spots as indicated by the cellular splicing marker 
SC35. These nuclear bodies do not contain promyelocytic leukemia protein, do not 
colocalize with nucleoli, and are therefore defined as nuclear speckles (184). The Tax 
Speckled Structures overlap with SC35 domains at their periphery, but contain other 
cellular proteins within their cores making them nuclear structures unique to Tax-
expressing cells. We found that expression of Tax results in the recruitment of usually 
diffuse nuclear proteins into the TSS. These proteins include DNA-PKcs, Chk2, and 
53BP1, proteins involved in DNA damage recognition and repair (129,134,168). The 
formation of TSS and the colocalization of SC35, DNA-PKcs, Chk2, and 53BP1 in the 
TSS with Tax places Tax near the cellular machinery for transcription, splicing, and 
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DNA damage response and checkpoint activation. This may help explain how Tax is able 
to affect so many different cellular proteins and functions simultaneously (134). 
Tax possesses both a nuclear localization signal (NLS) and a nuclear export signal 
(NES) and "shuttles" between the nuclear and cytoplasmic compartments (85,91,93,185). 
Tax has both nuclear and cytoplasmic functions, and the control of Tax localization to 
different subcellular compartments is critical to Tax function. While in the cytoplasm, 
Tax activates the NF-KB pathway by interacting with IKKy/NEMO and releasing NF-KB 
proteins to enter the nucleus and activate transcription of NF-KB-responsive genes (124). 
NF-KB transcription factors are key regulators of immune, inflammatory, proliferative, 
and apoptotic pathways (124). Constitutive NF-KB activation is a hallmark of HTLV-1-
infected and Tax-expressing cells and is believed to be necessary for transformation 
(124). Restriction of Tax localization to the cytoplasm would increase the activation of 
the NF-KB pathway and could possibly accelerate the process of transformation or 
exacerbate the immune response. The nuclear functions of Tax include transcriptional 
activation and repression, interaction with cell cycle proteins, and interactions with DNA 
damage recognition and repair proteins (129,132,134,168). Many of these nuclear 
functions are believed to occur in the TSS. Restriction of Tax to the nucleus and the TSS 
could result in increased genomic instability leading to accelerated transformation. 
Therefore the regulation of the localization of Tax to the TSS and other subcellular 




Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent for both 
adult T-cell leukemia (ATL) and a neurodegenerative disorder known as HTLV-
associated myelopathy/Tropical spastic paraperesis (HAM/TSP) as well as other 
subneoplastic conditions. In ATL, the immortalization and transformation of T-
lymphocytes can be attributed to the expression and activity of a single HTLV-1 viral 
protein, namely the transactivating protein Tax. Although the exact mechanism of Tax-
mediated transformation is unknown, studies indicate that Tax expression leads to 
genomic instability within the host cell by disruption of cellular DNA repair mechanisms, 
dysregulation of cell cycle, and interference with chromosome separation during mitosis. 
Tax has both nuclear and cytoplasmic functions, and the control of Tax 
localization to the different subcellular compartments is critical to regulation of Tax 
function. While in the cytoplasm, Tax activates transcription via the NF-KB pathway by 
directly binding to IKB kinase y/Nf-KB essential modulator (IKKy /NEMO) leading to 
phosphorylation and degradation of IKB. While in the nucleus, Tax interacts with cellular 
transcription factors to activate or repress transcription of cellular genes via the CREB 
and SRF pathways, and Tax interacts with proteins involved in DNA damage recognition 
and repair, cell cycle regulation, and chromosomal separation during mitosis. Tax enters 
the nucleus by its NLS and is directed to discrete nuclear foci referred to as Tax Speckled 
Structures (TSS). These TSS are interchromatin granules made of multi-protein 
complexes that contain Tax and cellular proteins involved in diverse functions such as 
transcription, DNA damage recognition and DNA repair. 
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In order to develop more effective treatments for ATL and HAM/TSP, we must 
obtain a more thorough knowledge of how Tax expression contributes to genomic 
instability within the host cell. The studies proposed in this dissertation are significant 
because they will provide insight into the underlying molecular events that localize Tax 
to specific nuclear sites that may regulate DNA damage response, DNA repair, and cell 
cycle checkpoint activation and where interference with these processes by Tax could 
lead to genomic instability. These studies may also provide specific therapeutic targets to 
prevent Tax-mediated cellular transformation by preventing Tax localization to TSS. 
Although the nuclear localization signal (NLS) for Tax has been previously 
defined, the domain in Tax that dictates TSS localization and cellular proteins that may 
be involved in the regulation of Tax subcellular localization remain unknown. The 
objective of this project is to characterize the regulation of the subcellular localization of 
Tax. The hypothesis is that the targeting of Tax into different subcellular and subnuclear 
compartments is critical to Tax function and is directed by internal domains, 
dimerization, and protein-protein interactions. This study will make a significant 
contribution to understanding how Tax localization and function affects cell functions 
leading to cellular transformation. 
The objective of this proposal will be accomplished by pursuing the following 
specific aims: 
Aim 1. Determine the domain(s) within Tax that dictate subnuclear localization to the 
Tax Speckled Structures. Using an extensive deletion mutagenesis approach, we will 
define the protein domain(s) that are required for proper targeting of Tax to the TSS. We 
will examine the functional significance of TSS targeting. 
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Aim 2. Determine the role of Tax dimerization in subcellular localization. Using Tax 
deletion mutants generated in Aim 1, we will perform dimerization assays and fine map 
the Tax dimerization domain. We will investigate the relationship between Tax 
dimerization, nuclear localization, and function. 
Aim 3. Determine the role of protein-protein interactions in Tax subcellular localization. 
Ubiquitylated forms of Tax are localized to the cytoplasm whereas sumoylated forms are 
localized in the nucleus. RNF4 was recently found to be a SUMO-dependent ubiquitin 
ligase protein with no previously identified targets. We will determine the effect of RNF4 
on Tax localization. 
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SECTION 3 
IDENTIFICATION OF TAX TSS LOCALIZATION SIGNAL 
Introduction 
Human T-cell Leukemia Virus Type 1 (HTLV-1) is the causative agent of 
both HTLV-1 Associated Myelopathy/ Tropical Spestic Paraperesis (HAM/TSP) and 
Adult T-cell Leukemia (ATL). In ATL, the transformation of lymphocytes is due to the 
expression of a single viral protein, Tax. Tax has both nuclear and cytoplasmic 
functions, thus necessitating that control of Tax localization to subcellular compartments 
is critical to overall Tax function (85,91,183). Tax has an NLS sequence in the N-
terminal region of the protein that is necessary and sufficient for nuclear localization 
(91,185,186). We previously showed that Tax "shuttles" between the nuclear and 
cytoplasmic subcellular compartments and identified a consensus NES sequence defined 
by amino acids 190 to 203 (85). Fine mapping mutational analysis of this region by 
Alefantis et al (93) clearly demonstrated a functional NES at this site. These signals 
presumably mediate interactions between Tax and karyopherins in the nuclear pore 
complex (NPC) to allow Tax to translocate through the nuclear membrane (187,188). 
The specific importins and exportins involved in Tax transport have yet to be identified, 
but recent studies indicate that Tax can be both imporedt and exported from the nucleus 
without the aid of carrier proteins or energy and can interact directly with the FG-
nucleoporins within the core of the NPC (189). Both the NLS and the NES of Tax are 
atypical. The NLS is rather large, involving the first forty-eight amino acids of Tax, and 
it is lacking in the highly basic residues that define classical NLSs (91,185,186). It 
contains a zinc finger domain (two zinc fingers) at amino acids 22-53 (185,186) and a 
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phosphorylation site at threonine 48 (86), and it overlaps most of the CREB-binding 
domain (106). The NES of Tax is a leucine-rich region between amino acids 188 and 202 
that is capable of mediating export of Tax via the CRM-1 pathway although with notably 
slower kinetics (85,93). This NES is believed to be masked in the native Tax protein and 
there is strong evidence that ubiquitination may "unmask" the NES in response to DNA 
damage (90). In fact, "nuclear" Tax is predominately sumoylated whereas 
"cytoplasmic" Tax appears to be primarily ubiquitylated (89). 
While in the cytoplasm, Tax activates transcription via the NF-KB pathway by 
directly binding to IKB kinase y/NF-KB essential modulator (IKKy /NEMO), leading to 
phosphorylation and degradation of IKB and release of NF-KB (96,123,124). In the 
nucleus, Tax interacts with cellular transcription factors to activate or repress 
transcription of cellular and viral genes via ATF/CREB, NF-KB and SRF pathways (107). 
Tax is capable of dimerization, and studies indicate that optimal transcriptional trans-
activation by Tax requires that it be in a dimeric or oligomeric form (91,100,101). 
Nuclear Tax also physically interacts with several cellular proteins and modulates their 
functions (129-143). While the NLS and NES provide one level of regulation for Tax 
localization, it is likely that there are other mechanisms at work in regulating Tax 
subcellular and subnuclear localization and thus function. 
In previous studies we and others have demonstrated that Tax enters the nucleus 
and is directed to discrete nuclear foci that we termed Tax Speckled Structures (TSS) 
(183,190). TSS coincide with interchromatin granules and consist of multi-protein 
complexes that partially overlap with subnuclear regions involved in splicing and 
transcription. We have also shown that Tax recruits cellular proteins involved in the 
DNA damage recognition and repair response into the TSS as well (129,134,168,191). 
The formation of TSS and the colocalization of SC35, DNA-PKcs, Chk2, and 53BP1 in 
the TSS places Tax near cellular machinery for transcription, splicing, DNA damage 
response and checkpoint activation and may explain how Tax is able to affect multiple 
cellular functions simultaneously (134,144). Although the nuclear localization signal 
(NLS) for Tax has been previously defined, the domain in Tax that dictates TSS 
localization remains unknown. 
Since the Tax NLS itself is so unusual, it may likely also contain the sequence 
responsible for directing Tax to the TSS. In order to separate the NLS function from the 
possible TSS targeting function, we have introduced an exogenous NLS from the large T 
antigen of S V40 to ensure transport of Tax into the nucleus. In this study, we transiently 
expressed Tax constructs containing partial deletions of the Tax NLS and evaluated the 
effect of each deletion on the protein's localization to TSS. We also created deletions 
along the length of Tax to test for possible TSS targeting function in regions outside of 
the NLS. We isolated a region containing the likely TSS targeting sequence and tested 
whether it alone could target a normally diffuse GFP protein into the TSS. In this manner 
we defined the minimal sequence that is both sufficient and necessary for dictating Tax 




The STaxGFP and SGFP expression vectors were constructed by inserting the 
tox-EGFP fusion or the EGFP ORF into the Smal site of pTriEx4-Neo (Novagen, 
Madison, WI) in frame with the amino terminal S- and His-tags. 
Site-Directed Mutagenesis 
The STaxGFP mutants were created with PCR-based site-directed deletion 
mutagenesis using Quickchange XL mutagenesis kit (Stratagene, La Jolla, CA). Forward 
and reverse primers were designed containing the desired mutations according to the 
manufacturer's protocol. Primers used were 5'(GGTCCCCCGAGGATCGCCCATCT 
CTG GGGG) and 3'(CCCCAGAGATGGGCGATCCTCGGGGGACC) for STax(dl-
29)GFP, 5'(CAAGGCGACTGGTGCCAGATCACCTGGGACCCC) and 3'(GGGGT 
CCCACGGTGAT CTGGCACCAGTCGCCTTG) for STax(d29-52)GFP, 5'(GGCCAC 
CTGTCCAGAGCATAAC ATTCCACCCTCC) and 3'(GGAGGGTGGAATGTTATG 
CTCTGGACAGGTGGCC) for STax(d52-99)GFP, 5'(CGCCAATCACTCATACAACC 
CCCGTTGTCTGCATGTACC) and 3'(GGTACATGCAGACAACGGGGGTTGTATG 
AGTGATTGGCG) for STax(d99-150)GFP, 5'(CCCTCTGGGGAGGCTCCGGGGCCC 
TAATAATTC) and 3'(GAATTATTAGGGCCCCG GAGCCTCCCCAGAGGG) for 
STax(dl50-202)GFP, 5'(CTATAAAATTTCCCTCACCACACCTATGATTTCCGGG 
CCC) and 3'(GGGCCCGGAAATCATAGGTGTGGTGAGGGAAATTT TATAG ) for 
STax(d202-254)GFP, 5'(GGACATTTACCGATGGCACGGGACATTTACCGAT 
GGCACG) and 3'(CGTGCCATCGGTAAATGTCCCGTGCCATCGGTAAATGTCC) 
for STax(d254-289)GFP, 5'(GGCCTACCACCCCTCAGAAAAAGAGGCAGATGAC) 
and 3'(GTCATCTGCCTCTTTTTCTGAGGGGTGGTAGGCC) for STax(d289-
322)GFP, and 5'(CCCCATTTCTCTACTTTTTAACGTGGATCCACCGGTCGCCAC 
C) and 3'(GGTGGC GACCGGTGGATCCACGTTAAAAAGTAGAGAAATGGGG) 
for STax(d322-353)GFP. Methylated STaxGFP plasmid derived from bacteria was used 
as the template, and mutagenic primers that would "loop out" the desired deletion were 
extended using PfuTurbo high-fidelity DNA polymerase. Following an 18 cycle PCR, the 
remaining methylated template was digested using the Dpnl provided, and the mutated 
PCR product was used to transform BLIO-Gold competent bacteria. Bacterial colonies 
growing under ampicillin selection were isolated, amplified, and plasmid DNA was 
purified using the Qiagen Miniprep Kit (Qiagen, Valencia, CA). The non-GFP versions 
of the Tax deletion mutants were created by digestion of the STaxGFP mutants (which 
have BamHl restriction sites flanking the GFP fusion) with BamHl followed by re-
ligation with DNA T4 ligase in the buffer provided by the manufacturer (Invitrogen, 
Carlsbad, CA). The S-NLS-TaxGFP constructs were created by inserting the SV40 T-
antigen nuclear localization signal in frame between the S tag and the tax-GFP fusion 
using the PCR-based Excite mutagenesis kit (Stratagene, La Jolla, CA). Primers used 
were 5' (GGTCCCCCGAGGATCGGATCCAAAAAAGAA GAGAAAGGTAATG 
GCCCACTTCCC) and 3' (CTGGGAAGTGGGCCATTACCTTTCTCTTCTTTTTTG 
GATCCGATCCTCGGGGGACC). STaxl-75GFP and SNLSTax50-75GFP were 
constructed by PCR-based mutagenesis using the Phusion site directed mutagenesis kit 
(Finnzymes Inc. Woburn, MA) using the primers 5' (GTGGATCCACCGGTCGCCA 
CCATG) and 3'(GAGTCGAGGGATAAGGAA CTGTAGAGCTGA) and 
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5'(GAGCATCAGAT CACCTGGGACCCC) and 3'(TACCTTTCTCTTCTTTTT 
TGGATCCGATCC) and using STaxGFP and S-NLS-TaxGFP as the templates. 
Sequences of all mutants were confirmed by DNA sequence analysis using a T7 forward 
primer (Davis Sequencing, Davis, CA), and expression was confirmed by transfection 
and immunoblot anaylsis as described below with polyclonal anti-Tax or anti-GFP 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). 
Cell Culture and Transfection 
HEK 293 cells and HeLa cells were maintained at 37°C in a humidified 
atmosphere of 5% CO2 in air in Iscove's modified Delbecco's medium supplemented 
with 10% fetal bovine serum (Cambrex, East Rutherford, NJ) and 1% 
penicillin/streptomycin (Invitrogen, Carlsbad, CA). Transfections were performed by the 
standard calcium phosphate precipitation method. Plasmid DNA for each construct was 
prepared using a Qiagen Plasmid Maxiprep Kit following manufacturer's protocol 
following amplification of transformed DH5a competent E. coli bacteria grown overnight 
under ampicillin selection. For immunoblotting assays, cells were plated in 100-mm 
plates at 2 x 106 cells per plate. For transcriptional activation assays cells were plated 
into 6-well plates at 2x 105 cells per well. The day 10 ug plasmid DNA in 10cm plates or 
3|a.g DNA in each single well of a 6-well plate in 2M CaC^ and 2x HEPES-buffered 
saline was added dropwise to the cells in fresh medium. The cells were washed 16 hours 
post-transfection and incubated at 37°C until harvest. Cells were harvested 48 hours post-
transfection following a single wash with lx phosphate-buffered saline in 400 ul of 
Mammalian Protein Extraction Reagent M-PER (Pierce, Rockford, IL) with protease 
inhibitor cocktail (Roche Applied Science, Palo Alto, CA) and immediately frozen. 
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Transcriptional Transactivation Assay 
HEK 293 cells were transiently transfected with 1 ug plasmid DNA for either 
pHTLV-LTR-Luciferase or pNFxB-Luciferase (Clontech, Mountain View, CA) and 2 ug 
plasmid DNA of the appropriate Tax construct to be assayed. Total DNA per 
transfection was normalized to 3ug total DNA with the addition of parental vector, 
pTriEx4-Neo (Novagen, Madison, WI). Cells were harvested 48 hours post-transfection 
by washing once with ice cold phosphate-buffered saline (PBS) and then lysing the cells 
in 400 ul IX Reporter/Lysis Buffer (Promega, Madison, WI). Lysates were immediately 
frozen at -80°C. Samples were allowed to thaw on ice, collected, and protein 
concentration was determined using the Bradford Protein Assay (Bio-Rad, Hercules, 
CA). A total of 1 (ig protein of each sample was applied to 100 ul of luciferase substrate 
(Promega, Madison, WI) and luciferase activity was immediately measured in a Turner 
TD-20/20 luminometer (Turner Designs, Sunnyvale, CA). Transcriptional activation was 
analyzed and expressed as fold activation over reporter alone (fold activation=l). All 
assays were performed three times with triplicates of each sample. 
Cell Cycle Analysis 
To determine the effect of the Tax mutants on cell cycle progression, HEK293T 
cells were transiently transfected with STaxGFP or deletion mutant as previously 
described. 48 hours post transfection, cells were washed once with PBS and collected by 
harvesting and centrifugation at lOOOrpm for 10 minutes at 4°C. Cells were fixed with the 
addition of 1 mL ice cold 70% ethanol and incubated at 4°C overnight. The ethanol was 
removed by centrifugation and cells were washed twice with 1 mL PBS. Cells were 
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resuspended in 1 mL propidium iodide solution (50 |j,g/mL propidium iodide and 100 
units/mL RNase A in PBS) and incubated for 30 minutes at room temperature with gentle 
rotation. The cells were washed once with PBS and then resuspended in 500uL PBS. 
DNA flow analysis was conducted on a FACScan (BD Biosciences, San Jose, CA) with 
Modfit LT software (Verity Software House, Topsham, ME). 
Immunofluorescence Confocal Microscopy 
HEK 293 cells or HeLa cells were seeded at lx 10 cells/well on ethanol-washed 
22-mm diameter glass coverslips in 6-well plates. Each well was transiently transfected 
with the indicated expression plasmids. After 48 hours, the cells were washed three times 
with PBS and subsequently fixed in 4% paraformaldehyde/PBS for 12 minutes at room 
temperature. Coverslips were washed twice with PBS, permeablized with methanol for 
two minutes at room temperature, washed three times with PBS, and incubated overnight 
at 4°C with primary antibodies diluted 1:1000 in 3% bovine serum albumin-PBS. Cells 
were washed twice with PBS/0.1% Tween 20 and twice with PBS and then incubated for 
1 hour at room temperature with AlexaFluor-488 (green) or -594 (red) secondary 
antibodies (Molecular Probes, Eugene, OR) and TO-PRO-3' iodide (Molecular Probes, 
Eugene, OR) diluted 1:1000 in 3% BSA-PBS. Coverslips were washed twice with BSA-
PBS and twice with PBS and then mounted on glass slides using Vectashield with 4', 6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA). Confocal 
fluorescent images were acquired on a Zeiss LSM 510 confocal microscope (Carl Zeiss, 
Jena, Germany) using argon (488nm), HeNel (543nm), and HeNe2 (633nm) lasers with 
63 x objective oil lens with 2x zoom and imaged with LSM Image Browser software 
(Carl Zeiss, Jena, Germany). 
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Complementation Analysis 
A myc-tagged version of the NLS mutant, mycTax(d29-52) was coexpressed with the 
TSS targeting mutant, STax(d52-99)GFP. Localization of the coexpressed proteins was 
visualized with confocal immunofluorescence microscopy as previously described. Tax 
and mutants were detected by direct fluorescence of GFP. Myc-tagged Tax and myc-Tax 
mutant were detected by indirect immunofluorescence staining with rabbit polyclonal 
anti-myc tag primary antibody (Abeam) at a dilution of 1:1000 followed by goat anti-
rabbit secondary antibody conjugated to Alexafluor 594 (Molecular Probes, Eugene, OR) 
at 1:1000 dilution. 
Results 
Deletion Scanning Mutational Analysis of Tax 
We constructed a series of consecutive 25-52 amino acid deletions that covered 
the length of the Tax protein as depicted in Figure 1 A. These constructs included an N-
terminal S tag for protein purification and a C-terminal GFP tag for localization studies. 
Expression of each of the mutants was confirmed by imunnoblot analysis (data not 
shown). We then analyzed each of the mutants for transcriptional ^cms-activation, cell 
cycle dysregulation, and subcellular localization. Nearly all of the deletion mutants had 
no transcriptional frvms-activation for either an HTLV-1 responsive or an NFKB-
responsive promoter/reporter (Figure IB). The only exception was the C-terminal 
deletion mutant STax(d322-353)GFP which had a fr-arcs-activation activity higher than 
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FIG.l. Tax Mutant design and Transcriptional Activation. A.) Diagram depicting 
domains in STaxGFP deleted in scanning series of Tax mutants. B.) Transcriptional 
transactivation of mutants on HTLVl-LTR-Luciferase and NF-KB-Luciferase 
promoters/reporters. 293T cells were transiently transfected with reporter and either 
STaxGFP (STG) or deletion mutant, and lysates were analyzed for relative activity 















































FIG. 2. Cell Cycle Analysis of 293T cells Expressing Tax Mutants. The 
histograms represent the distribution of cells throught the cell cycle 
measured by flow cytometry and analyzed by Modfit. Cells were transiently 
transfected with plasmid DNA for pTri-Ex4 Neo (mock), STaxGFP, or Tax 
deletion mutant as indicated. The percentage of cells in G2/M is shown. 
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in the G2/M phase of the cell cycle (Figure 2, B). Cell cycle analysis of the Tax mutants 
demonstrated that only STax(d322-353)GFP had an effect on cell cycle progression 
comparable to that of wildtype Tax (Figure 2, J). The other Tax mutants were unable to 
induce the accumulationof the cells in G2/M and the cell cycle distribution resembled 
that of the mock-transfected cells (Figure 2, A, C-I). These results were not surprising 
since earlier studies indicate that almost any mutations of Tax, including point mutations, 
completely ablate Tax activity (92). Confocal microscopy studies revealed that the 
mutants displayed one of three phenotypes: localization in discrete nuclear foci, diffuse 
nuclear localization, or cytoplasmic localization (Figure 3). One mutant deleted in part of 
the Tax NLS, STax(dl-29)GFP, was weakly able to enter the nucleus and form foci 
while the other NLS mutant, STax(d29-52)GFP was completely confined to the 
cytoplasm. Mutants deleted in the mid region of Tax including STax(d99-150)GFP, 
STax(dl50-202)GFP, STax(d202-254)GFP, and STax(d254-289)GFP were also confined 
to the cytoplasm. The two C-terminal deletion mutants, STax(d289-322)GFP and 
STax(d322-353)GFP formed nuclear foci. One mutant, STax(d52-99)GFP displayed a 
diffusely nuclear localization with no apparent foci. 
Tax Mutant Localization into TSS 
We next confirmed whether the foci formed by the nuclear Tax mutants were true 
Tax Speckled Structures (TSS) as defined as having colocalization with the cellular 
marker of transcriptional hot spots, spliceosome component 35 (SC35). Three of the four 
mutants were able to form TSS (Figure 4) including STax(dl-29)GFP, and two C-
terminal Tax deletions, STax(d289-322)GFP and STax(d322-353)GFP. One construct, 
STax(d52-99)GFP, was able to enter the nucleus, but did not form TSS, demonstrating 
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STaxGFP STax(d1-29)GFP STax(d29-52)GFP 
STax(d52-99)GFP | STax(d99-15Q)GFP| STax(d15Q-202)GFP 
STax(d202-254)GFP STax(d254-289)GFP STaxfd289-322)GFP 
STax(d322-353)GFP 
FIG. 3. Localization of STaxGFP Mutants. Confocal microscopy images of Tax 
mutants transiently expressed in 293T cells. Cells were fixed, and nuclei were stained 
with TO-PRO-3' iodide at a dilution of 1:1000. Tax expression is detected via the GFP 
fusion. 
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FIG. 4. Colocalization of Tax Mutants with SC35 in TSS. Confocal microscopy 
images of fixed 293T cells transiently expressing nuclear Tax mutants. SC35 was 
detected with mouse anti-SC35 antibody (Invitrogen) at a dilution of 1:1000 followed 
by goat anti-mouse Alexafluor 594-conjugated secondary antibody at a dilution of 
1:1000 (Molecular Probes). Nuclei were stained with TO-PRO 3' iodide (Molecular 
Probes) at a dilution of 1:1000. 
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the retention of NLS function and implicating this deleted region as a TSS specific 
targeting sequence. 
A Novel N-Terminal Domain Is Sufficient for Localization of Tax to TSS 
In order to more precisely define the TSS targeting domain, we designed 
constructs containing only the first 75 amino acids of Tax inserted in frame between the 
N-terminal S tag and the C-terminal GFP. This construct was able to target GFP into TSS 
that were indistinguishable from those of wildtype Tax (Figure 5, A and C). A construct 
containing only the S tag and GFP was expressed diffusely throughout the cell with no 
targeting to nuclear foci (Figure 5B). The nuclear localization signal (NLS) for Tax is 
defined as amino acids 2 to 48 (91,185,186), and deletion of this region would interfere 
with nuclear translocation. In order to determine if the TSS targeting domain is distinct 
from the NLS, we inserted an exogenous NLS from the SV40 Large T Antigen (Tag) in 
frame between the S tag and Taxl-75GFP. This insertion did not interfere with the 
targeting of GFP to TSS (Figure 5D). We then deleted the first 49 amino acids of Tax to 
create S-NLS-Tax50-75GFP and observed that this construct was also able to target the 
GFP fusion into the TSS (Figure 5E). This indicates that the Tax speckle targeting signal 
(TSTS) is outside of the Tax NLS and within amino acids 50-75 of Tax. 
Cytoplasmic Phenotype is Not Cell- or Fusion Tag-Specific 
In our original scanning series of deletion mutants of Tax, there were four mutants 
that were confined to the cytoplasm despite having an intact nuclear localization signal. 
In order to determine whether this was a phenotype specific to 293 T cells, we expressed 
the same Tax deletion constructs in HeLa cells. Confocal microscopy analysis revealed 
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FIG. 5. Confocal Microscopy Analysis of the Localization of Tax N-terminal 
Peptides Fused to GFP. Fixed 293T cells transiently expressing STaxGFP, SGFP, or N-
terminal fragments of Tax fused to GFP were assayed for TSS formation as confirmed by 
colocalization with SC35. 
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that the nuclear exclusion of the mid-region Tax deletion mutants was not unique to 293T 
cells as the same cytoplasmic localization of these mutants was observed in the HeLa 
cells (Figure 6). 
We next questioned whether the localization of our mutants was altered by the 
addition of the large C-terminal GFP fusion. To be certain that the GFP was not the cause 
of the mislocalization of the mutants, we removed the GFP fusion from each of the Tax 
mutants using restriction digestion and re-ligation and used confocal microscopy to assay 
localization. As summarized in Figure 7, the removal of the GFP fusion did not restore 
nuclear translocation to any of our mid-region mutants. 
We hypothesized that the large deletions in our mid-region Tax mutants affected 
the functioning of the Tax NLS, and therefore the addition of an exogenous NLS would 
restore nuclear translocation. We added the SV40 T-antigen NLS in frame after the S tag 
to each of the five cytoplasmic mutants. The exogenous NLS was able to partially restore 
nuclear translocation for the mutant that was deleted in part of the Tax NLS, STax(d29-
52)GFP (Fig. 8A), but not for the non-NLS mutants (Fig 8B-E). This suggests that Tax 
nuclear translocation is dependent on more than the nuclear localization signal alone, and 
additional regulatory mechanisms must exist for Tax subcellular localization. 
Complementation Analysis of NLS Mutant and TSS Targeting Mutant 
We decided to examine the effect of cotransfection of the NLS mutant with the 
TSS targeting mutant. Expression of a myc-tagged version of the NLS mutant alone 
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STax(d202-254)GFP STax(d254-289)GFP 
FIG. 6. Localization of Mid-region Tax Mutants in HeLa cells. HeLa cells were 
transiently transfected with plasmid DNA for mid-region Tax deletion mutants that had 
displayed cytoplasmic localization in 293T cells. HeLa cells were fixed and stained for 
SC35 and nuclei as previously described. 
44 
FIG. 7. Confocal Microsopy Analysis of Tax Deletion Mutants After Removal of GFP 
Fusion. 293T cells were transiently transfected with plasmid DNA for STax deletion 
mutants without the C-terminal GFP tag as indicated. Cells were fixed and stained for 







FIG. 8. Localization of Tax Mutants with Exogenous NLS Tagging. The NLS from 
SV40 T-antigen was added in frame to nuclear-excluded Tax mutants by site-directed 
mutagenesis, and constructs were transiently expressed in HEK 293 cells. Cells were 
fixed and stained for nuclei and SC35. 
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(myc-Tax(d29-52) resulted in no nuclear translocation, and expression of the TSS 
targeting mutant alone STax(d52-99)GFP resulted in no TSS formation as previously 
observed (Figure 9A). However, coexpression of the NLS mutant with the TSS targeting 
mutant resulted in normal nuclear translocation and TSS formation (Figure 9A). To 
confirm that the foci formed by the coexpression of the mutants were true TSS, we 
expressed the GFP-fusion version of each mutant either alone or in combination (Figure 
9B), and observed colocalization of each with SC35. Coexpression resulted in the 
formation of true TSS. Complementation by these two different domain mutants confirms 
that the NLS and TSTS are distinct domains with the ability to independently target Tax 
into the nucleus and into TSS, respectively. This assay also suggests there is dimerization 
between the Tax mutants and supports a connection between dimerization and nuclear 
localization. 
Discussion 
In addition to the known regulation of Tax localization via the NLS, the NES, and 
post-translational modification by sumoylation and ubiquitylation, we have now 
described a novel mechanism for the regulation of Tax subcellular localization. This 
mechanism involves a signal that directs Tax into nuclear bodies called Tax Speckled 
Structures. These structures are nuclear protein complexes located at sites partially 
overlapping with transcriptional hot spots. There are several known types of large protein 
complexes present in the nucleus including speckles, paraspeckles, Cajal bodies, gems, 
and Nuclear Domain 10 (ND10) (179)/ promelocytic leukemia (PML) bodies (178). 
A. TOPRO TOPRO STax(d52-99)GFP 
MycTax(d29-52) Merge MycTax(d29-52) Merge 
Anti-sc35 Merge Anti-sc35 Merge Anti-sc35 Merge 
FIG. 9. Complementation Analysis of NLS mutant and TSS targeting mutant. (A) Confocal microscopy images of 
expression of MycTax(d29-52) or STax(d52-99)GFP expressed alone or in combination. Myc-tagged Tax mutant was detected 
with rabbit anti-myc antibody (Abeam) followed by Alexfluor 594 goat anti rabbit secondary antibody. B: Colocalizatioa with 
SC35 of STax(d29-52)GFP alone, STax(d52-99)GFP alone, or STax(d29-52)GFP with STax(d52-99)GFP. 4^ 
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These nuclear bodies are believed to form in response to gene expression and contain 
characteristic sets of nuclear proteins that are continually associating and dissociating 
with other nuclear components while remaining in distinct subnuclear regions (192). 
Nearly all of these nuclear structures contain subpopulations of splicing factors, but each 
is distinguished by the presence of a nuclear protein unique to each structure (180). 
Nuclear Speckles are interchromatin granule clusters (IGCs) that contain the pre-
messenger RNA splicing machinery including small nuclear ribonucleic proteins 
(snRNPs), non-snRNP splicing factors, and spliceosome subunits such as the spliceosome 
component 35 protein (SC35) (178). 
The Tax Speckled Structures colocalize with SC35 domains at their periphery, do 
not contain promyelocytic leukemia protein, and do not colocalize with nucleoli, and are 
therefore defined as nuclear speckles (184). However, they are structures unique to Tax-
expressing cells in that they contain various other non-splicing cellular proteins as well. 
These proteins include DNA-PKcs, Chk2, and 53BP1, proteins involved in DNA damage 
recognition and repair (129,134,168). The targeting of Tax to TSS and the colocalization 
of SC35, DNA-PKcs, Chk2, and 53BP1 in the TSS with Tax places Tax near cellular 
machinery for transcription, splicing, and DNA damage response and checkpoint 
activation. 
Studies of intranuclear protein targeting indicate that it is a multistep process 
requiring at least two trafficking signals: one for nuclear import (the NLS) and one for 
mediating interactions with the nuclear matrix (the nuclear matrix-targeting signal) to 
direct the protein to a specific subnuclear domain (193-195). In our study, we found that 
the Tax speckle targeting signal (TSTS) was physically distinct from the NLS and could 
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function independently to direct Tax to its specific intranuclear site. The TSTS for Tax is 
enriched for proline residues, a characteristic shared by many splicing speckle proteins, 
but it does not contain the arginine-serine (RS domain) motif common to targeting 
signals of splicing speckle components (196-199). This may reflect the unique nuclear 
address of TSS and the ability of Tax to form complexes with diverse nuclear proteins in 
addition to those involved in mRNA processing. 
Another feature within our identified TSTS is an SH3 binding domain. The Src 
Homology 3 (SH3) domain belongs to a family of modules that recognize proline-rich 
ligands (200-202). The SH3 domains regulate protein localization, enzymatic activity and 
often participate in the assembly of multicomponent signaling complexes (203,204). The 
minimal sequence requirement for the SH3 domain ligands is the PxxP motif (205). This 
sequence is contained within our identified TSTS, and interactions through this domain 
may help mediate interactions with the nuclear matrix proteins to direct Tax into TSS. 
The targeting of Tax to TSS via the TSTS may have particular implications for 
the development of Adult T-cell Leukemia. Barseguian et al found that mutations in the 
transcription factor AML-1 (core binding factor a/ polyoma enhancer binding protein 2) 
gene that abrogated the nuclear matrix targeting signal resulted in concomitant loss of 
transcriptional activity (195,206). The AML-1 gene is one of the most frequently mutated 
genes in human leukemias, and the authors suggested that the fidelity of transcriptional 
control may be dependent on the proper localization of transcriptional regulatory proteins 
like AML-1 to specific subnuclear regions. In promyelocytic leukemia, the normal 
subnuclear localization of the PML protein is altered from discrete foci to diffusely 
distributed throughout the nucleus, providing another example of dysregulation of 
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intranuclear targeting leading to a leukemic phenotype (207,208). In the case of HTLV-1 
infection, the ability of Tax to perturb the subnuclear organization of the cell by 
redirecting nuclear proteins into TSS and away from their normal intranuclear sites may 




INFLUENCE OF DIMERIZATION ON TAX LOCALIZATION 
Introduction 
HTLV-1 is the causative agent of ATL and HAM/TSP. In ATL, the 
transformation of CD4 + lymphocytes is the result of the expression of the viral protein 
Tax. This protein is a transcriptional transactivator that influences cellular and viral gene 
expression and can physically interact with cellular proteins and modulate their functions. 
Previous studies have established that Tax forms dimers and that optimal transcriptional 
transactivation by Tax requires Tax dimerization (100,101). However, how and where in 
the cell this dimerization occurs remains unknown. Tax has pleiotropic activity requiring 
that it shuttle between the nuclear and cytoplasmic compartments, and the regulation of 
the subcellular localization of Tax is therefore critical to Tax function (85). Tax 
localization is partially regulated by previously defined nuclear localization and nuclear 
export signals in Tax (91,185). Lamsoul et al have demonstrated that Tax localization is 
also influenced by post-translational modifications including sumoylation and 
ubiquitylation, adding another layer of complexity to the regulation of Tax localization 
(89). 
In our previous studies, we observed Tax deletion mutants that were unable to 
accumulate in the nucleus despite having intact nuclear localization signals, indicating 
that nuclear accumulation requires more than a localization signal alone. The four non-
NLS mutants of Tax that were nuclear excluded contained deletions within a region that 
has been previously defined as the Tax dimerization domain (100,101). This 
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dimerization domain is usually large, taking up nearly half of the Tax protein itself. 
Within the large dimerization domain are three subdomains that have been shown to be 
critical for Tax dimerization (101). Although these subdomains have been identified, 
their interdependence for Tax dimerization has not been established. Each of our first 
three Tax mid-region mutants is missing one of the dimerization subdomains. The 
remaining mutant is missing only a few amino acids of the larger dimerization domain. 
We hypothesized that dimerization of Tax may be prerequisite to Tax nuclear localization 
and may explain why our mid-region Tax mutants failed to accumulate in the nucleus. 
In this study, we examined the link between Tax dimerization and its nuclear 
localization. We confirmed that the mid-region Tax mutants missing one or two 
subdomains of the dimerization domain were partially or completely deficient for 
dimerization. We demonstrate that the mutants missing a single subdomain for 
dimerization retained the ability to weakly dimerize with wildtype Tax, and this 
dimerization was associated with rescue of nuclear localization. However, the single 
subdomain mutants were not able to homodimerize or to heterodimerize with another 
single subdomain mutant, and were therefore unable to rescue nuclear localization. We 
demonstrate that the mutant missing two dimerization subdomains is unable to dimerize 
with wildtype Tax and is not rescued for nuclear localization. We created a Tax mutant 
that was inducible for dimerization and correlated an increase in nuclear accumulation 
with an increase in the concentration of the chemical dimerizer. In addition, we show that 
dimerization between mutants missing either the NLS or the TSS targeting domain allows 
for complementation between the mutants and restoration of nuclear localization and TSS 




The myc-tagged Tax construct mycTax was a kind gift from Ralph Grassmann. 
The mycTax(D29-52) construct was created by site-directed mutagenesis of mycTax using 
the QuickchangeXL mutagenesis kit (Stratagene, La Jolla, CA) and the primers 
5'(CAAGGCGACTGGTGCCAGATCACCTGGGACCCC) and 3'(GGGGTCCCACG 
GTGAT CTGGCACCAGTCGCCTTG). Construction of the Tax deletion mutant 
STax(d99-l50)GFP was described previously. The Tax deletion mutant STax(d99-
150/202-254)GFP was constructed using the Excite Mutagenesis kit (Stratagene, La 
Jolla, CA) using the primers 5'(CCCTCTGGGGAGGCTCCGGGGCCC TAATAATTC) 
and 3'(GAATTATTAGGGCCCCG GAGCCTCCCCAGAGGG) and using STax(d99-
150)GFP as the template. The inducible dimerization construct S-Tax(d99-150)-Fv-GFP 
was created by amplifying the Fv domain ofpC^FvlE (ARIAD Pharmaceutical) adding 
CM restriction sites with the primers 5'(ACCATCGATGGAGT GCAGGTGGAG 
ACTT) and 3'(ACCATCGATTTCGAGTTTTAGAAGCTCCAC), digesting the PCR 
product with Clal and then inserting in frame into the Clal site located at Tax amino acid 
58 within STax(d99-150)GFP. 
Cell Culture and Transfection 
HEK 293 cells were maintained at 37°C in a humidified atmosphere of 5% CO2 
in air in Iscove's modified Delbecco's medium supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin (Invitrogen). Transfections were performed by the 
standard calcium phosphate precipitation method. For S-bead purification and Western 
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blotting assays, cells were plated in 100-mm plates at 2 x 10 cells per plate. For 
transcriptional activation assays cells were plated into 6-well plates at 2x 105 cells per 
well. The following day 10 ug plasmid DNA in 2M CaCh and 2x HEPES-buffered saline 
was added dropwise to the cells in fresh medium. The cells were washed 16 hours post 
tranfection and incubated at 37°C until harvest. Cells were harvested 48 hours post 
transfection following a single wash with lx phosphate-buffered saline in 400 ul of 
mammalian protein extraction reagent M-PER (Pierce) with protease inhibitor cocktail 
(Roche Applied Science) and immediately frozen at -80°C. 
Immunofluorescence Confocal Microscopy 
HEK 293 cells were seeded at lx 105 cells/well on ethanol-washed 22-mm 
diameter coverslips in 6-well plates. Each well was transiently transfected with the 
indicated expression plasmids. After 48 hours the cells were washed three times with 
PBS and subsequently fixed in 4% paraformaldehyde/PBS for 12 minutes at room 
temperature. Coverslips were washed twice with PBS, permeablized with methanol for 
two minutes at room temperature, washed three times with PBS, and incubated overnight 
at 4°C with primary antibodies diluted 1:1000 in 3% bovine serum albumin-PBS. Cells 
were washed twice with PBS/0.1% Tween 20 and twice with PBS and then incubated for 
1 hour at room temperature with AlexaFluor secondary antibodies (Molecular Probes, 
Eugene, OR) and TO-PRO-3 iodide (Molecular Probes, Eugene, OR) diluted 1:1000 in 
3% BSA-PBS. Coverslips were washed twice with BSA-PBS and twice with PBS and 
then mounted on glass slides using Vectashield with 4',6-diamidino-2-phenylindole 
(Vector Laboratories, Burlingame, CA). Confocal fluorescent images were acquired on a 
Zeiss LSM 510 confocal microscope (Carl Zeiss, Jena, Germany) using argon (488nm), 
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HeNel (543nm), and HeNe2 (633nm) lasers at 63x objective with 2* zoom and imaged 
with LSM Image Browser software (Carl Zeiss, Jena, Germany). 
S-TaxGFP Purification 
Lysates from transiently transfected HEK 293 cells were assayed for total protein 
concentration using the Bradford Protein Assay (Bio-Rad, Hercules, CA) and normalized 
using a BSA standard curve. For each sample, 500 [ig protein was brought to a total 
volume of 500 ul with M-PER (Pierce, Rockford, IL), and 150 ul of S-protein agarose 
beads (Novagen, Madison, WI) were applied to the sample. Lysates and beads were 
incubated at 4°C overnight with rotation and then centrifuged at 500*g for 5 minutes at 
4°C. Supernatants were removed and the beads were washed three times with 1ml S-
bead Bind/Wash buffer (20 mM Tris-HCL pH 7.5, 150mM NaCl, 0.1% TritonX-100). 
Purified S-tagged proteins and bound proteins were eluted from the beads by addition of 
100 ul 2x Laemmli Sample Buffer (Bio-Rad, Hercules, CA) with 5% (3-mercaptoethanol 
and incubation of beads at 100°C for 10 minutes. Supernatants containing purified 
proteins were loaded on an 8-12% gradient SDS-PAGE gel (Bio-Rad, Hercules, CA) and 
separated by electrophoresis, transferred to Immobilon-P membrane (Millipore, Billerica, 
MA) by semidry transfer method and subjected to immunoblot analysis. 
Immunoblot Analysis 
Proteins separated by electrophoresis were transferred to Immobilon-P membrane 
(Millipore, Billerica, MA) using a Trans-blot SD semi-dry transfer cell (Bio-Rad, 
Hercules, CA) with 400 milliamps applied for 50 minutes in transfer buffer (25mM Tris, 
200mM glycine, 20% methanol, 0.1% SDS). Membranes were then blocked for one hour 
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at room temperature in lx Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE). 
Primary antibodies against the myc-tag (Invitrogen, Carlsbad, CA) were diluted 1:1000 in 
IX Odyssey Blocking Buffer were applied to the membranes and allowed to interact 
with the membranes at 4°C overnight on an orbital shaker. Membranes were washed four 
times for five minutes with 1%PBS-Tween. LI-COR Odyssey secondary antibodies 
diluted in IX Odyssey Blocking Buffer with 0.5% SDS and 0.5% Tween were applied at 
a concentration of 1:20000, and were incubated with the membranes for one hour at room 
temperature on an orbital shaker while protected from light. Membranes were washed 
four times for five minutes with PBS-1% Tween20 and then stored in PBS and protected 
from light until analyzed. Blots were scanned and analyzed with a LI-COR Odyssey 
scanner and software. 
Dimerization Assay 
Full length myc-tagged Tax was coexpressed with STaxGFP or mutant missing 
one or two dimerization subdomains, STax(d99-150)GFP and STaxfd99-150/202-
254)GFP, respectively, in HEK 293 cells. Lysates were subjected to S-bead purification 
followed by electrophoresis and immunoblot analysis. STaxGFP and mutants were 
detected with mouse monoclonal anti-GFP antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) at 1:1000 dilution followed by Odyssey goat anti-mouse IR Dye680 (LI-COR 
Biosciences, Lincoln, NE) at 1:20000 dilution. Copurified myctax was detected by 
polyclonal anti-myc-tag (Abeam,) at a dilution of 1:1000 followed by Odyssey goat anti-
rabbit IR Dye800 (LI-COR) at a dilution of 1:20000. Membranes were scanned and 
analyzed with LI-COR Odyssey scanner and software. 
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Complementation Analysis 
Full length myc-tagged Tax was coexpressed with all mutants deficient for 
nuclear translocation or TSS formation. Mid-region Tax mutants were coexpressed in 
pairs: STax(d99-150GFP) with STax(dl50-202)GFP, STax(d202-254)GFP with 
STax(d254-289)GFP, STax(d99-150)GFP with STax(d202-254)GFP, and STax(dl50-
202)GFP with STax(d254-289)GFP. Localization of the coexpressed proteins was 
visualized with confocal immunofluorescence microscopy as previously described. Tax 
and mutants were detected by direct fluorescence of GFP. Myc-tagged Tax and myc-Tax 
mutant were detected by indirect immunofluorescence staining with rabbit polyclonal 
anti-myc tag primary antibody (Abeam) at a dilution of 1:1000 followed by goat anti-
rabbit secondary antibody conjugated to Alexafluor 594 (Molecular Probes, Eugene, OR) 
at 1:1000 dilution. 
Induced Dimerization Assay 
STax(d99-150)-Fv-GFP was transiently transfected in HEK 293 cells seeded onto 
glass coverslips at 2 x 105 cells per well in 6-well plates. 48 hours after transfection, the 
cells were treated with AP20187 from the Argent Homodimerization kit (ARIAD 
Pharmaceutical, ) at a concentration of 0 nM, 0.01 nM, 0.1 nM, 1.0 nM, 10 nM, 50 nM, 
or 100 nM for 24 hours. Cells were washed, fixed with 4% paraformaldehyde/PBS, 
permeablized with methanol, and processed as previously described for confocal 
microscopy analysis. Images were analyzed for nuclear accumulation using Metamorph 
Image Analysis software (Molecular Devices, Sunnyvale, CA). Briefly, 100 cells of each 
condition were analyzed for green nuclear fluorescence expressed as a percentage of total 
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green cell fluorescence for each individual cell. For each cell analyzed, a region of 
interest (ROI) was traced around the nuclear membrane, and the area contained within the 
ROI was analyzed for total fluorescence intensity for the GFP emission wavelength. Then 
a second ROI was drawn around the plasma membrane of the same cell, and that region 
was analyzed for total fluorescence intensity for the same wavelength to give the total 
cell fluorescence intensity. The percentage of nuclear fluorescence intensity was 
determined by dividing the nuclear intensity by the total cell intensity for each individual 
cell. 
Results 
Tax Mid-region Mutants are Deficient for Dimerization 
To test if our mid-region mutants were deficient for dimerization, we 
coexpressed a myc-tagged full length Tax construct with STaxGFP or mutant missing 
either one subdomain or two subdomains of the dimerization domain, STax(d99-
150)GFP or STax(d99-150/202-254)GFP, respectively. We then examined dimerization 
by S-bead purification of the S-tagged Tax lysates followed by immunoblot analysis for 
the myc-tagged Tax (Figure 10A). Full length STaxGFP was able to bind to myc-tagged 
Tax demonstrating strong dimerization between the two full length proteins (Fig. 10A, 
lane 7). A reduced signal for myctax in lane 6 indicates that STax(d99-150)GFP could at 
least weakly dimerize with full length Tax while STax(d99-150/202-254)GFP displayed 
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FIG. 10. Dimerization Assay of Tax Mid-region Mutants. A) Full length myc-
tagged Tax was coexpressed with STaxGFP or mutant missing 1 or 2 dimerization 
subdomains, STax(d99-150)GFP and STax(d99-150/202-254)GFP, respectively. 
Ability of STaxGFP and mutants to dimerize with mycTax was assayed by S-bead 
purification of mutants followed by immunoblot analysis for mycTax using polyclonal 
anti-myc-tag and for the Tax mutants using monoclonal anti-GFP . B) Dimerization 
assay of remaining single dimerization subdomain mutants STGdl 50-202, STGd202-
254, & STGd254-289. 
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S-beads alone (lane 8). Lanes 1-4 show that the abundance of mycTax was not limiting in 
the reactions in any of the samples. Similar results of weak dimerization were observed 
with mycTax and the other mid-region Tax mutants (Fig. 10B, lanes 8-10). 
Rescue of Nuclear Translocation and TSS formation by Full Length Tax 
Since the mutants missing only one subdomain of the mid-region dimerization 
domain were still able to weakly dimerize with full length Tax, we assayed the effect of 
coexpression of full length Tax on the subcellular localization of the mutants. 
Immunofluorescence confocal microscopy studies revealed that coexpression of full 
length Tax with the mutants was able to partially restore nuclear localization to those 
mutants missing only one subdomain of the dimerization domain (Figure 11, C-F) but not 
for the mutant missing two subdomains of the dimerization domain (Figure 11, G). In 
addition, the coexpression of full length Tax with the NLS mutant or the TSS targeting 
domain mutant was able to restore nuclear localization or TSS formation to these as well 
(Figure 11, A-B). Complementation analysis of the mutants indicated that coexpression 
of mutants deleted in different subdomains of the dimerization domain was not able to 
rescue nuclear localization as no green fluorescence is observed in the nuclei (Figure 12). 
Complementation Analysis of NLS Mutant and TSS Targeting Mutant 
Earlier we had coexpressed the Tax NLS mutant and TSS targeting mutant and 
observed that the mutants could rescue each other. This was similar to our previously 
observed rescue with wildtype Tax. Expression of a myc-tagged version of the NLS 









FIG. 11. Rescue By Full Length Tax of the Nuclear Localization of Tax Deletion 
Mutants. Full length mycTax and Tax deletion mutants were transiently cotransfected 
into 293 T cells. Tax mutants were detected by GFP. MycTax was detected by indirect 
immunofluorescence with rabbit anti-myc primary antibody f(Abeam) followed by 
Alexafluor594 goat anti-rabbit secondary antibody. (Molecular Probes) 
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FIG. 12. Confocal Microscopy Analysis of Coexpression of Dimerization 
Subdomain Mutants. 293T cells were transiently cotransfected with plasmids deleted 
for different dimerization subdomains. Cells were fixed and stained for nuclei and 
SC35. 
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the TSS targeting mutant alone (STax(d52-99)GFP) resulted in no TSS formation as 
previously observed (Figure 9A). However, coexpression of the NLS mutant with the 
TSS targeting mutant resulted in normal nuclear translocation and TSS formation (Figure 
9A). Coexpression resulted in the formation of true TSS. Complementation by these two 
different domain mutants suggests there is dimerization between the Tax mutants and 
supports a connection between dimerization and nuclear localization. 
To definitively link Tax dimerization and nuclear localization, we designed a Tax 
construct that contains an inducible dimerization domain, STax(d99-l50)-Fv-GFP. This 
assay is based on the binding domain of the human protein FK506 Binding Protein 
(FKBP) and its ability to bind to the immunosuppressive drugs FK506 and rapamycin. Fv 
is a modified version of the FKBP binding domain containing a phenylanaline to valine 
substitution that increases the affinity of a rapamycin derivative, AP20187, for the Fv-
fusion protein by 1000-fold over the wildtype protein. AP20187 is a small molecule able 
to crosslink any two proteins containing the FKBP binding domain thus inducing 
dimerization (ARIAD Pharmaceutical). The expression of STax(d99-150)-Fv-GFP in the 
absence of the chemical dimerizer AP20187 resulted in a completely cytoplasmic 
localization of the protein. Upon the addition of increasing concentrations of the 
dimerizer, the Tax protein began to accumulate in the nucleus in a dose-dependent 
manner from less than 1% to more than 40% nuclear accumulation (Figure 13). This 
demonstrates that Tax must be in a dimeric or oligomeric form in order to localize in the 
nucleus. The site of insertion of the dimerizer domain was within the TSS targeting 
sequence, which disrupted the speckle localization signal and prevented the induced 
dimers from localizing into TSS. 
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FIG. 13. Effect of Induced Dimerization on Nuclear Accumulation of 
Tax Mutant. (A) Confocal microscopy images of cells expressing 
STax(d99-150)-Fv-GFP treated with OnM, InM, lOnM, or lOOnM of the 
chemical dimerizer AP20187. Cells were fixed and stained for SC35 and 
nuclei as previously described. (B) Quantitation of the nuclear accumulation 
of STax(d99-150)-Fv-GFP with increasing concentration of dimerizer. 
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Discussion 
The second novel mechanism described in this study for regulation of Tax 
subcellular localization is Tax dimerization as a requirement for nuclear accumulation. 
There are numerous examples of proteins that must dimerize or oligomerize prior to 
nuclear translocation including the Human Cytomegalovirus protein ppUL44 and the 
cellular protein p53 (209,210). Other proteins such as the AP-1 family including c-Jun, 
JunD, JunB and c-Fos enter the nucleus as monomers but require heterodimerization in 
order to remain in the nucleus (211). In our studies, we were able to link the inability of 
Tax mutants to accumulate in the nucleus with a deficiency in dimerization. Those Tax 
mutants that retained the ability to weakly dimerize with wildtype Tax were also able to 
weakly accumulate in the nucleus with wildtype Tax. Induced dimerization of a 
previously cytoplasmic Tax dimerization mutant resulted in restored nuclear 
translocation. A mutant lacking an NLS and therefore unable to enter the nucleus on its 
own was able to dimerize to either wildtype Tax or the TSTS mutant and thentranslocate 
into the nucleus. Our studies definitively link dimerization and nuclear accumulation and 
that this dimerization occurs in the cytoplasm as a prerequisite to nuclear entry. 
Previous studies on the dimerization of Tax have suggested that the N-terminal 
zinc finger domain is important for Tax self-association (100,101). These findings were 
based on yeast two-hybrid assays where an N-terminal mutant of Tax failed to interact 
with wildtype Tax. Our functional complementation assay between the NLS mutant, 
STax(d29-52)GFP, which is also missing the zinc-finger domain, and the TSTS mutant 
demonstrates that the zinc finger domain is not required for dimerization within the cell 
(Fig. 9). Also, the addition of an exogenous NLS to the same zinc finger NLS Tax 
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mutant was able to restore nuclear localization and subsequent accumulation, providing 
more evidence that the zinc finger domain is dispensable for Tax self-association (Fig.8). 
Additional questions also remain as to the stoichiometry of Tax self-association. 
Our complementation assays between the NLS mutant and TSTS mutant suggest that the 
Tax self-interaction exists in a one-to-one relationship. In addition, for the processes of 
nuclear localization and subnuclear targeting, our studies suggest that a single copy of 
each signal is sufficient for targeting the multimer into its proper location. The inability 
of the dimerization subdomain mutants to complement each other to restore nuclear 
accumulation, however, suggests that a higher order oligomer, such as a tetramer, may be 
required to overcome the absence of a part of the dimerization domain. This is supported 
by our findings in the induced dimerization assay. The design of the heterologous 
"dimerizer" domain is such that only dimers, and not higher order oligomers, are formed 
upon the addition of the chemical dimerizer. Although induced dimerization was able to 
increase the nuclear accumulation of the mutant protein, it did not result in a total 
restoration of nuclear accumulation to wildtype level (Figure 13). This suggests that 
under certain conditions, Tax may oligomerize. Tax oligomerization could provide even 
more complex regulation of Tax functions. Oligomerization could generate new 
intermolecular interfaces to improve stability, control the accessibility and specificity of 
active sites, and increase the number of cellular binding partners for Tax, and may help 
explain how this single protein has such a wide range of pleiotropic activities. 
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SECTION 5 
INFLUENCE OF CELLULAR PROTEINS ON TAX LOCALIZATION 
Introduction 
Human T-cell Leukemia Virus Type-1 (HTLV-1) infection can lead to Adult T-
cell Leukemia (ATL), HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis 
(HAM/TSP), and several other subneoplastic conditions. The viral transactivating 
protein, Tax, encoded by the pX region, has been recognized by its pleiotropic actions to 
play a critical role in transformation. Although many studies have demonstrated changes 
in cellular proteins through protein-protein interactions with Tax 
(126,131,134,168,175,212), fewer studies have investigated the effect of these cellular 
protein interactions on the localization and function of Tax. 
Tax is a predominantly nuclear phosphoprotein with the ability to shuttle between 
the nuclear and cytoplasmic compartments (85,86). Recent evidence indicates that Tax is 
post-translationally modified by ubiquitylation and sumoylation, and these modifications 
direct the subcellular localization of Tax (89,90,213). 
Ubiquitin is a small 76-amino acid polypeptide that is present in all eukaryotic 
cells (214). Modification of a cellular protein by the addition of ubiquitin involves the 
covalent attachment of ubiquitin to lysine residues within the target protein. 
Ubiquitylation is a multistep, ATP-dependent process involving three individual enzymes 
(215) . The first enzyme (El) activates the ubiquitin, the second enzyme (E2) ligates the 
ubiquitin to the target protein specified by the third enzyme (E3) (214). The 
ubiquitylation of a protein can result in its activation, affect its localization, or direct it to 
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the proteosome for degradation (215). Often the number of ubiquitins added can partially 
determine the fate of the target protein. Monoubiquitylation often has a regulatory 
function while conjugation of a polyubiquitin chain of four or more ubiquitins onto a 
target protein can target it for degradation by the proteosome (216). 
The Small Ubiquitin-like Modifier (SUMO) is similar to ubiquitin in that it is a 
small polypeptide that is conjugated to a target protein on lysine residues by a series of 
three enzymes (217). Sumoylation results in similar changes in the activation and 
location of the modified protein as ubiquitylation. Lamsoul et al have previously 
demonstrated that ubiquitylation of Tax is associated with its accumulation in the 
cytoplasm while sumoylation of Tax results in nuclear entry and TSS formation (89,90). 
In particular, the lysine residues located at amino acids 280 and 284 of Tax have been 
implicated as the critical sites for both sumoylation and ubiquitylation of Tax leading to 
the nuclear or cytoplasmic accumulation of Tax respectively (89,90). Although it is clear 
that both ubiquitylation and sumoylation of Tax play a role in Tax regulation, the cellular 
proteins involved in the ubiquitylation and sumoylation of Tax have yet to be identified. 
In this study, we have identified a novel physical interaction between Tax and the 
ring finger protein 4, RNF4, a cellular ubiquitin E3 ligase with no known cellular target 
(215). RNF4, also known as small nuclear ring finger protein (SNURF), preferentially 
targets sumoylated proteins for ubquitination, and as such is referred to as a SUMO-
targeted ubiquitin ligase (STUbL) (215). We show, through the work of our collaborator 
Oliver Kerscher, that RNF4 is able to ubiquitylate previously sumoylated Tax in vitro. 
We show that the overexpression of RNF4 causes an egress of Tax from the Tax 
Speckled Structures and the nucleus to form a perinuclear ring in the cytoplasm. We 
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mapped the domain in Tax responsible for its interaction with RNF4 to be between Tax 
amino acids 202 and 254. Further, we demonstrate that increasing expression of RNF4 
results in decreasing Tax /ram'-activation of the HTLV-1-LTR responsive promoter (a 
nuclear function of Tax) and increasing Tax frwM-activation of the NF-KB responsive 
promoter (a cytoplasmic function of Tax) in a dose-dependent manner. In this way we 
demonstrate that RNF4 is able to affect both the localization and function of Tax. 
Experimental Procedures 
Plasmids 
The STaxGFP and SGFP expression vectors were constructed by inserting the 
tec-EGFP fusion or the EGFP ORF from HisTaxGFP and C-EGFP vectors respectively 
into the Smal site of pTriEx4-Neo (Novagen, Madison, WI) in frame with the amino 
terminal S- and His-tags. The Tax double point mutant STaxK280/284R-GFP was created 
using STaxGFP as the template and the Quickchange Site-directed Mutagenesis Kit 
(Strategene, La Jolla, CA) with the primers 5'(TCCTCCTTTATATTTCACAGATTTC 
AA) and 3' (GGGGTGGTAGGCCCTGGT TTGAAA). pRNF4-GFP andpGFP-RNF4 
were kind gifts from Oliver Kerscher. 
Cell Culture and Transfection 
HEK 293 cells were maintained at 37°C in a humidified atmosphere of 5% CO2 
in air in Iscove's modified Delbecco's medium supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA). Transfections were 
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performed by the standard calcium phosphate precipitation method. For S-bead 
purification and Western blotting assays, cells were plated in 100-mm plates at 2 x 106 
cells per plate. For transcriptional activation assays cells were plated into 6-well plates at 
2x 105 cells per well. The following day 10 jag plasmid DNA for 10cm plates or l-6ug in 
a single well of a 6-well plate in 2M CaCl2 and 2x HEPES-buffered saline was added 
dropwise to the cells in fresh medium. The cells were washed 16 hours post-transfection 
and incubated at 37°C until harvest. Cells were harvested 48 hours post-transfection 
following a single wash with lx phosphate-buffered saline in 400 ul of mammalian 
protein extraction reagent M-PER (Pierce, Rockford, IL) with protease inhibitor cocktail 
(Roche Applied Science, Palo Alto, CA) and immediately frozen at -80°C. 
Immunofluorescence Confocal Microscopy 
HEK 293 cells were seeded at lx 105 cells/well on ethanol-washed 22-mm 
diameter coverslips in 6-well plates. Each well was transiently transfected with the 
indicated expression plasmids. After 48 hours the cells were washed three times with ice 
cold phosphate buffered saline (PBS) and subsequently fixed in 4% 
paraformaldehyde/PBS for 12 minutes at room temperature. Coverslips were washed 
twice with PBS, permeablized with methanol for two minutes at room temperature, 
washed three times with PBS, and incubated overnight in a humidifying chamber at 4°C 
with primary antibodies diluted in 3% bovine serum albumin-PBS. Rabbit polyclonal 
anti-Tax antibody and mouse anti-SC35 antibody (Invitrogen, Carlsbad, CA) were used 
at a dilution of 1:1000. Cells were washed twice with PBS/0.1 % Tween 20 and twice 
with PBS and then incubated for 1 hour at room temperature with AlexaFluor594 anti-
rabbit and anti-mouse secondary antibodies and TO-PRO-3' iodide (Molecular Probes, 
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Eugene, OR) diluted 1:1000 in 3% BSA-PBS. Coverslips were washed twice with BSA-
PBS and twice with PBS and then mounted on glass slides using Vectashield with 4',6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA). Confocal 
fluorescent images were acquired on a Zeiss LSM 510 confocal microscope (Carl Zeiss, 
Jena, Germany) using argon (488nm), HeNel (543nm), and HeNe2 (633nm) lasers with 
63* objective oil lens with 2* zoom and imaged with LSM Image Browser software 
(Carl Zeiss, Jena, Germany). 
S-TaxGFP and RNF4 Binding Assay 
Lysates from HEK 293 cells transiently transfected with STaxGFP, SGFP, or 
STaxGFP deletion mutants and GFP-RNF4 were assayed for total protein concentration 
using the Bradford Protein Assay (Bio-Rad, Hercules, CA) and normalized using a BSA 
standard curve. 500 ug protein was brought to a total volume of 500 ul with M-PER 
(Pierce, Rockford, IL) with protease inhibitors (Roche,) for each sample, and 150 ul of S-
protein agarose beads (Novagen, Madison, WI) were applied to the sample. Lysates and 
beads were rotated for 30 minutes at room temperature and then centrifuged at 500xg for 
5 minutes at 4°C. Supernatants were removed and the beads were washed three times 
with 1ml S-bead Bind/Wash buffer (20 mM Tris-HCL pH 7.5, 150mM NaCl, 0.1% 
TritonX-100). Purified S-tagged proteins and bound proteins were eluted from the beads 
by addition of 100 pi 2 x Laemmli Sample Buffer (Bio-Rad, Hercules, CA) with J3-
mercaptoethanol and incubation of beads at 100°C for 10 minutes. Supernatants 
containing purified proteins and bound proteins were loaded on an 8-12% gradient SDS-
PAGE gel (BioRad, Hercules, CA) and separated by electrophoresis, transferred to 
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Immobilon-P membrane (Millipore, Billerica, MA) by semidry transfer, and subjected to 
immunoblot analysis. 
Immunoblot Analysis 
Proteins separated by electrophoresis were transferred to Immobilon-P membrane 
(Millipore, Billerica, MA) using a Trans-blot SD semi-dry transfer cell (Bio-Rad, 
Hercules, CA) with 400 milliamps applied for 50 minutes in transfer buffer (25mM Tris, 
200mM glycine, 20% methanol, 0.1% SDS). Membranes were then blocked for one hour 
at room temperature in 1 x Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE). 
Primary antibodies diluted in 1 x Odyssey Blocking Buffer were applied to the 
membranes and allowed to interact with the membranes at 4°C overnight on an orbital 
shaker. Membranes were washed four times for five minutes with PBS-l%Tween20. LI-
COR Odyssey secondary antibodies diluted in 1 x Odyssey Blocking Buffer with 0.5% 
SDS and 0.5% Tween20 were applied at a concentration of 1:20000, and were incubated 
with the membranes for one hour at room temperature on an orbital shaker while 
protected from light. Membranes were washed four times for five minutes with PBS-1% 
Tween20 and then stored in PBS and protected from light until analyzed. Blots were 
scanned and analyzed with a LI-COR Odyssey scanner and software (LI-COR 
Biosciences, Lincoln, NE). 
Transcriptional Transactivation Assay 
HEK 293 cells were transiently transfected with 1 p.g plasmid DNA for either 
pHTLV-LTR-Luciferase or pNFxB-Luciferase (Clontech, Mountain View, CA) with 0-5 
ug pGFP-RNF4 and 1 \ig STaxGFP plasmid DNA. Total DNA per transfection was 
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normalized to 6(ig total DNA per well with the addition of parental vector, pTriEx4-Neo 
(Novagen, Madison, WI). Cells were harvested 48 hours post-transfection by washing 
once with ice cold PBS and then lysing in 400 ul 1 x Reporter/Lysis Buffer (Promega, 
Madison, WI). Lysates were immediately frozen at -80°C. Samples were allowed to 
thaw on ice, collected, and protein concentration was determined using the Bradford 
Protein Assay (Bio-Rad, Hercules, CA). A total of 1 ug protein of each sample was 
applied to 100 ul of luciferase assay substrate (Promega, Madison, WI), and luciferase 
activity was immediately measured in a Turner TD 20/20 luminometer. Transcriptional 
activation was analyzed and expressed as fold activation over reporter alone (fold 
activation=l). All assays were performed three times with triplicates of each sample. 
Results 
Tax interacts with RNF4 
Previous studies in our laboratory provide evidence that Tax binds to member of 
the ring finger (RNF) family (unpublished observation). We were interested in whether 
Tax could bind to a specific RNF family protein, RNF4, which is a SUMO-targeted 
ubiquitin ligase with no known target. In our previous studies we designed expression 
constructs for Tax with an affinity S-tag (STax, STaxGFP) that allows for purification of 
Tax and Tax-binding complexes from transfected cell lysates. In order to determine if 
RNF4 is able to interact with Tax, we transfected GFP-RNF4 either alone or with SGFP, 
STaxGFP, or a mutant of Tax with point mutations at lysines 280 and 284, 
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FIG. 14. Copurification of GFP-RNF4 and Tax. 293T cells were transiently 
transfected with SGFP, STaxGFP, or STaxK280/284R in the presence or absence of 
GFP-RNF4. Lysates were subjected to S-bead purification.Purified S-taggged proteins 
and bound proteins were separated by SDS-PAGE and subjected to immunoblot 
analysis with detection by polyclonal anti-GFP antibody. 
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two lysine residues that were previously shown to be critical to Tax localization. We then 
purified the S-tagged proteins with S-protein agarose beads, separated them by 
electrophoresis, and then subjected them to immunoblot analysis using an anti-GFP 
antibody that would detect the SGFP , the STaxGFP, the Tax mutant and the RNF4-GFP. 
Purified STaxGFP also precipitated GFP-RNF4 indicating that they interact in the same 
complex (Fig. 14, lane 2). The S-beads did not bind to GFP-RNF4 alone demonstrating 
the specificity of the S-beads for the S-tagged proteins, and purified SGFP did not 
coprecipitate GFP-RNF4 (Fig. 14, lanes 4 and 7) demonstrating that the interaction was 
specific to Tax and RNF4. Surprisingly, the Tax double point mutant that could not be 
ubiquitylated or sumoylated, STaxK280/284R-GFP, retained the ability to interact with 
RNF4 (lane 6), indicating that the RNF4-Tax interaction does not require the 
ubiquitylating activity of RNF4. 
RNF4 Overexpression Leads to Cytoplasmic Accumulation of Tax 
We next wanted to determine if the interaction between Tax and RNF4 causes 
them to colocalize in TSS. Confocal microscopy studies indicated that overexpression of 
RNF4 resulted in an egress of Tax from the nucleus (Figure 15). The Tax Speckled 
Structures were lost as Tax exited the nucleus to form a perinuclear ring within the 
cytoplasm of the cotransfected cells. 
RNF4 Ubiquitylates Tax In Vitro 
RNF4 is an ubiquitin ligase that preferentially targets sumoylated proteins. Earlier 
studies by Lamsoul et al demonstrated that Tax can be both sumoylated and ubiquitylated 
and that ubiquitylation on Tax lysine residues 280 and 284 resulted in cytoplasmic 
DAPI GFP-RNF4 DAPI GFP-RNF4 
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FIG. 15. Confocal Microscopy Analysis of GFP-RNF4 and STax Coexpression. 
293T cells were transiently transfected with GFP-RNF4 and STax. Cells were 
fixed and subjected to indirect immunofluorescence staining with polyclonal anti 
Tax antibody followed by Alexafluor 594-conjugated goat anti rabbit antibody. 
GFP was used to detect RNF4. Nuclei were stained with TO-PRO- 3'-iodide and 
DAPI. 
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localization of Tax while sumoylation on the same lysine residues resulted in nuclear 
localization (89). Our findings that overexpression of RNF4 led to an egress of Tax from 
the nucleus led us to question whether RNF4 could ubiquitylate Tax. Through an in vitro 
ubquitination assay, our collaborator, Dr. Oliver Kerscher at the College of William and 
Mary, demonstrated that RNF4 is able to ubiquitylate Tax (Figure 16). Following 
preincubation with RNF4, Tax was able to form high molecular weight adducts 
corresponding to ubiquitylated Tax (Fig. 16 lanes 4 and 5). This ubiquitination of Tax 
required the presence of ATP and was mediated through ubcl3, an E2 ubiquitin ligase. 
When free SUMO was added to the reaction, the free SUMO outcompeted Tax in binding 
RNF4 and prevented the ubiquitination of Tax (Fig. 16 lanes 6 and 7). A complete 
description of the experimental procedure for this assay is in Appendix A of this 
dissertation. 
RNF4 Overexpression Affects Tax Trans-Activation 
We have demonstrated that Tax and RNF4 interact with each other in a complex, 
and that this interaction can result in the ubiquitylation of Tax in vitro. We also observed 
that overexpression of RNF4 results in a relocalization of Tax from the nucleus to the 
cytoplasm. Next we wanted to see if this relocalization of Tax could affect its trans-
activation activity on both the HTLV-1 LTR, a nuclear function of Tax, and on the NF-
KB pathway, a cytoplasmic function of Tax. We performed promoter/reporter 
transcriptional activation assays for STaxGFP in the presence of increasing RNF4 
expression. We found that RNF4 expression resulted in a decrease in the activation of 
HTLV-LTR-Luc by STaxGFP (Figure 17A). The activation of HTLV-LTR-Luc was 
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FIG. 16. Ubiquitylation of Tax-MBP After Preincubation with RNF4. 
Tax fused to maltose binding protein (MBP) was allowed to incubate with 
RNF4 (lanes 1-2, 5-7) and then was subjected to in vitro ubiquitylation 
assay in the absence of ATP (lane 1), without the E2 ligase ubcl3/mms2 
(lane 2), without the E3 ligase RNF4 (lane 3), or with all of these +/- MBP 
(lanes 4-5). In lanes 6 and 7 free SUMO was added. The reaction products 
were separated by SDS-PAGE and subjected to immunoblot analysis with 
anti-Tax antibody. 
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FIG. 17. Mapping the Tax-RNF4 Interacting Domain. 293FT cells were transiently 
transfected with SGFP, STaxl-150GFP, STaxGFP, or deletion mutants of Tax in the 
presence or absence of RNF4-GFP. Lysates were subjected to S-bead purification, and 
bound proteins were eluted, separated by SDS-PAGE, and subjected to immunoblot 
analysis with polyclonal anti-GFP antibody (Invitrogen). 
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of RNF4. We found that increasing RNF4 expression resulted in an increase in the trans-
activation of NF-KB-Luciferase activity from 30-fold to nearly 60-fold (Figure 17B). 
Mapping the Tax-RNF4 Interaction Domain 
We next wanted to determine the region in Tax responsible for its interaction with RNF4. 
We expressed each of our Tax deletion mutants either alone or with RNF4-GFP in 293FT 
cells. We then purified the Tax mutants using the S-bead purification followed by SDS-
PAGE and immunoblot analysis as described previously. There was no interaction 
between RNF4-GFP and SGFP (Figure 18, lane 1) or between RNF4-GFP and a Tax 
mutant containing only the N-terminal 150 amino acids of Tax, STaxl-150GFP (lane 2). 
We were able to copurify RNF4-GFP with STaxGFP (lane 4), STax(d254-289)GFP (lane 
8), STax(d289-322)GFP (lane 10), and with STax(d322-353)GFP (lane 12). Only the 
deletion mutant STax(d202-254)GFP failed to interact with RNF4-GFP (lane 6) 
suggesting that this region is required for the interaction of Tax with RNF4. 
Discussion 
Many of the functions of Tax are accomplished through direct protein-protein 
interactions with cellular partners. Although there have been many studies to examine 
the effect of Tax expression on the functions of cellular proteins, there have been fewer 
studies of how these interactions may affect the activities of Tax. In this study we have 
identified a novel cellular binding partner for Tax, the ubiquitin ligase RNF4. This 
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Fig. 18. Effect of RNF4 Expression on the Transcriptional Activation 
Activity of Tax. 293T cells were transiently transfected with 
promter/reporter constructs, STaxGFP, and increasing concentrations of 
RNF4-GFP. Lysates were subjected to luciferase assays and fold 
activation over reporter alone (fold acitivation=1) is indicated for each 
sample. 
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identified specific cellular target for ubiquitylation (215). STUbLs possess a SUMO-
interacting motif (SIM) that allows them to interact with sumoylated proteins and 
proteins containing SUMO-like domains (SLDs) (218). RNF4 contains four putative 
SIMs, and targets proteins that have been modified by the addition of multiple SUMO 
peptides (216). Unlike ubiquitylation which can mark a protein for degradation via the 
proteosome, sumoylation may prevent degradation and result in accumulation of 
sumoylated proteins (219). Therefore, the interaction between STUbLs and sumoylated 
proteins may serve to target the previously sumoylated proteins for ubiquitin-mediated 
proteosomal degradation (218). 
Our studies demonstrate that RNF4 is able to ubiquitylate previously sumoylated 
Tax in vitro. These findings provide the first specific protein target for RNF4. This 
interaction was found to be sumoylated-Tax-specific since it could be outcompeted by the 
addition of free SUMO. Tax is sumoylated on multiple lysines including those at 
residues 280 and 284 making it an attractive target for the poly-SUMO-specific activity 
of RNF4 (89,90,213,216). We show that this ubiquitylation results in a relocalization of 
Tax from its normal nuclear location in Tax Speckled Structures to the cytoplasm where 
it forms a perinuclear ring. One possible explanation for the relocalization of Tax to the 
cytoplasm following ubiquitylation may be to promote proteosomal degradation of Tax. 
Earlier studies of Tax ubiquitylation , however, indicated that the addition of ubiquitin 
resulted in an increase in Tax binding to proteosomes without proteosomal degradation of 
Tax (213,220). This same study indicated that ubiquitylation of Tax resulted in a loss of 
transcriptional activation of the viral LTR (213). We were able to link the ubiquitin-
induced cytoplasmic relocalization of Tax to a decrease in the transcriptional trans-
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activation of the HTLV-LTR, which is a nuclear function of Tax, and an increase in the 
frYmy-activation of NF-KB by Tax, which is a cytoplasmic function of Tax. The loss of 
transcriptional activation, therefore, is more likely a result of the relocalization of Tax 
rather than an inactivation of Tax by ubiquitylation. 
Our studies suggest that the domain within Tax that mediates its interaction with 
RNF4 lies between amino acids 202 and 254. This region lies just N-terminal to the two 
lysine residues shown to be involved in linking ubiquitylation and relocalization of Tax. 
Interestingly, the mutation of these two residues from lysines to arginines which would 
prevent ubiquitylation did not prevent the interaction between Tax and RNF4. 
The purpose for Tax ubiquitylation may be to regulate the nucleocytoplasmic 
shuttling of Tax. Our laboratory has previously shown that Tax is able to shuttle between 
the nucleus and cytoplasm via an NLS and an NES (85). Lamsoul et al have shown that 
sumoylation of Tax results in nuclear localization while ubiquitylation results in 
cytoplasmic localization (89). Alefantis et al have suggested that the NES of Tax may 
often be "masked" by protein folding or other means (93). We have shown in this study 
that Tax must enter the nucleus as a dimer and that it is directed into TSS by a specific 
TSS targeting signal. Putting all of these findings together, we suggest a possible model 
for Tax shuttling. Since the Tax NES is within the dimerzation domain, Tax dimerization 
in the cytoplasm may mask the NES while having no effect on the functions of the N-
terminal NLS and TSTS. The Tax dimer is then sumoylated by an as yet unidentified 
SUMO ligase and translocates into the nucleus where it is directed into TSS. The 
sumoylated Tax is targeted by RNF4 for ubiquitylation, and this modification may either 
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cause disruption of the Tax dimer or another conformational change that exposes the Tax 





We have identified two novel mechanisms for the regulation of Tax subcellular 
localization. The first is the Tax Speckle Targeting Sequence that mediates interactions 
between Tax and the nuclear matrix to direct Tax into its discrete nuclear foci. We found 
that this sequence is physically and functionally separate from the previously identified 
nuclear localization signal of Tax. This region from Tax amino acids 50 to 75 was found 
to be sufficient for targeting the normally diffuse green fluorescent protein (GFP) into 
Tax-like nuclear speckles. Deletion of the region in Tax from amino acids 52 to 99 
resulted in loss of TSS targeting and demonstrates that this region is also necessary for 
TSS targeting. Tax Speckled Structures are nuclear structures unique to Tax in that they 
contain proteins from both the transcription/splicing machinery and from the DNA 
damage recognition and repair machinery (134,168,183). The targeting sequence for TSS, 
therefore, may have some similarity to targeting signals for other nuclear speckle proteins 
without the requirement for complete homology. Our identified TSTS is enriched in 
proline residues, is relatively short in length, and is predominantly unstructured based on 
predicted motif searches. These are all features shared by other nuclear speckle-
associated targeting signals (196,199,206). Our signal differs from previously identified 
speckle-targeting sequences in that it does not possess an arginine/serine motif common 
to many speckle proteins (195,197,198). 
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The second novel means of regulating Tax subcellular localization is through Tax 
dimerization. Although it was previously demonstrated that Tax could self-associate to 
form dimers, the significance of dimerization in localization had not been demonstrated 
(100). Tax deletion mutants that were deficient for dimerization were unable to localize 
into the nucleus. Coexpression with wildtype Tax was able to partially restore nuclear 
accumulation and correlated with weak dimerization between the single dimerization 
subdomain mutants and wildtype Tax. Complete loss of dimerization capability resulted 
in inability to be rescued by wildtype and failure to localize to the nucleus. We found that 
deletion mutants missing one of the two critical targeting signals, the NLS or the TSTS, 
were able to heterodimerize with each other and rescue the deficient localization by 
functional complementation. Finally, restoration of self-association through induced 
dimer formation resulted in restoration of nuclear accumulation. 
We also identified a novel functional and physical relationship between Tax and 
the ubiquitin ligase RNF, providing the first known target for RNF4. Previous studies 
have shown that Tax can be ubiquitynylated and that this modification is associated with 
cytoplasmic localization of Tax (89,213). The ubiquitin ligase involved in this 
modification, however, has not been identified. We have shown that Tax can be 
ubiquitylated by RNF4 in vitro and that increased expression of RNF4 leads to a 
relocalization of Tax from the nucleus to the cytoplasm. We demonstrated that Tax and 
RNF4 can interact physically in a complex, and we have mapped the domain in Tax 
responsible for this interaction with RNF4 to be the region between amino acids 202 and 
254. This region is upstream from the two lysine residues in Tax (280 and 284) that are 
believed to be modified by ubiqitinylation and associated with Tax relocalization (89). 
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We also showed that this relocalization resulted in changes in the ^raw-activation 
function of Tax. Increased RNF4 expression resulted in a decrease in the transcriptional 
activation of the viral LTR, a nuclear function of Tax, while increasing activation of NF-
KB, a cytoplasmic function of Tax. These findings have broadened our knowledge of the 
regulation of Tax subcellular localization and have identified new physical and functional 
relationships for Tax. 
Significance of Findings 
It is estimated that there are currently 20-30 million people infected with HTLV-1 
(12). Out of those people about 1.5 million will develop one of the two debilitating and 
invariably fatal diseases ATL or HAM/TSP (31). In certain distinct geographical areas 
such as the Caribbean, as many as 3-4% of the population is seropositive for HTLV-
1(31). In Japan, it is estimated that there are 1.2 million people infected with HTLV-1, 
and there are 800 new cases of ATL diagnosed each year (9,32). Current therapies are 
ineffective in treating these two conditions and provide little relief and hope for patients 
and their families (64). 
The mechanisms by which Tax is able to induce cellular transformation are still 
unknown. Any new information that we gain regarding the functioning of Tax is a step 
toward developing possible new therapies. There is significant evidence that the 
transformation potential of Tax is related to its ability to dysregulate cell cycle, DNA 
repair, and apoptosis through its direct protein-protein interactions and drafts-activation 
functions. In order to achieve such diverse cellular effects, Tax must interact with cellular 
88 
binding partners in several subcellular compartments. The regulation of the subcellular 
localization of Tax is therefore critical to the functions of Tax. 
In this study we have gained significant knowledge in the regulation of the 
subcellular localization of Tax. Our identification of a Tax Speckle Targeting Signal that 
shares characteristics with other nuclear matrix targeting sequences suggest that Tax is 
able to interact with the nuclear matrix proteins and opens up an entire new category for 
Tax cellular binding partners. Also, mutations that remove or alter intranuclear-targeting 
signals are prevalent in leukemias and have been linked to altered localization of 
transcription factors within the nucleus (193-195). In some leukemias, these mutations in 
the intranuclear targeting of transcription factors reduce fidelity of gene expression by 
influencing the organization or assembly of machineries involved in transcription and 
mRNA processing (193). The expression of Tax and its ability to relocalize cellular 
proteins to TSS may have a similar effect as mutation of the intranuclear targeting signal 
for these transcription factors. By binding to Tax, the transcription factor may be 
removed from its normal subcellular address to a new site within TSS, leading to similar 
dysregulation of transcription and mRNA processing as would result from mutation of its 
intranuclear targeting signal. This would provide yet another means for Tax to influence 
transcription and effect changes leading to transformation. 
We have also supplied additional insight into regulation of the nuclear 
localization of Tax through dimerization. There are many examples of proteins that must 
be in dimeric or oligomeric form to enter or to remain in the nucleus such as the HCMV 
processivity factor ppUL44, the Ku proteins, the AP-1 family members c-Fos, c-Jun, 
JunB and JunD, and the cellular protein p53 (209-211,221). Previous studies of Tax 
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indicated that Tax is capable of forming dimers and that optimal ^raw-activation by Tax 
requires Tax dimerization (100-102). We are the first to show that nuclear localization of 
Tax requires Tax self-association. Since Tax is a predominantly nuclear protein, this 
finding is quite significant and suggests that Tax spends a majority of its time in a 
dimeric state. The formation of Tax dimers may also serve to "mask" the nuclear export 
signal of Tax resulting in nuclear retention. The nuclear export signal for Tax is located 
between amino acids 190 and 203 (85,93), and this area partially overlaps one of the 
previously identified dimerization subdomains (101). Although this signal was found to 
be CRM-1 dependent for Tax export, normal Tax export is CRM-1 independent (93). 
Alefantis et al suggest that this NES is usually "masked" in Tax (93). Disruption of 
dimerization, then, could be one means for uncovering the NES and relocalizing Tax 
from the nucleus into the cytoplasm. 
Finally, we have identified a novel interaction between Tax and RNF4. This is a 
significant finding because there has been no previously identified specific target for the 
ubiquitnylating activity of RNF4. We have shown that RNF4 can ubiquitylate Tax in 
vitro and suggest that RNF4 may be the ubiquitin ligase responsible for Tax 
ubiquitylation in vivo. This is also significant because we were able to link this 
posttranslational modification with a change in both the localization and fr-am'-activation 
function of Tax. Recent studies by Gatza et al have indicated that Tax is ubiquitylated 
following DNA damage due to genotoxic stress or UV irradiation and that this 
ubiquity lation results in the nuclear export of Tax via a CRM-1 dependent pathway 
(90,222). Our findings suggest that this ubiquitylation of Tax may be accomplished 
though RNF4, but additional studies will be required to confirm this role for RNF4. 
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Future Directions 
During these studies we identified a new localization sequence, the TSS targeting 
signal (TSTS), that directs Tax into TSS. We determined that Tax must dimerize as a 
prerequisite for nuclear translocation, and we identified a novel binding partner for Tax, 
RNF4. In the process we have developed several tools that will be invaluable in future 
studies of Tax. These tools can be used to further develop the Tax interactome, to 
establish Tax functions which occur in the TSS, to link oligomerization of Tax with Tax 
function, and to investigate other possible targets for RNF4. 
These tools will be useful in defining the Tax interactome. We began these studies 
with a scanning series of Tax mutants with deletions of 29 to 54 amino acids in length. 
Although these constructs were originally designed to map the TSTS domain of Tax, they 
may be used in future studies to begin fine mapping the domains in Tax required for 
interactions with previously identified Tax-binding proteins such as DNA-PKcs, Chk2, 
and 53BP1. As our continued studies of the Tax interactome identify new Tax binding 
partners, we can employ these constructs to define the Tax domains required for each 
interaction. In addition, our earlier studies using these mutants revealed one mutant, 
STax(d322-353)GFP, that displayed transcriptional /nms-activation activity higher than 
that of wildtype Tax (Fig. IB). This same mutant was the only one that induced a G2/M 
arrest comparable to that of wildtype in the cell cycle analysis (Fig. 2), and it expressed 
extremely high levels of protein that seemed to localize to the nucleus more efficiently 
than wildtype Tax. Studies by Tsuji et al suggested that the C-terminus of Tax may 
contain a cytoplasmic retention signal (189). STax(d322-353)GFP may be a more potent 
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transcriptional activator due to the absence of the C-terminal region, and future studies 
with this construct may be able to confirm the role of this region of Tax. 
We can use the Tax NLS mutant, STax(d29-52)GFP, and the TSTS mutant, 
STax(d52-99)GFP, for studies to link Tax subcellular localization and function. Since 
each of these mutations results in specifically altered Tax localization to the cytoplasm or 
to the nucleus but outside of the TSS, we can analyze these mutants for known Tax 
functions and assign each function to a particular subcellular compartment. Specifically, 
we can analyze the ability of the TSTS mutant to perform known Tax functions and 
determine which Tax functions are associated with Tax Speckled Structures and which 
require only nuclear entry. Possible Tax functions to be assayed could include the 
activation of DNA-PKcs, induction of micronuclei, and the modulation of Chk2 kinase 
activity. We were also able to demonstrate functional complementation between these 
two mutants resulting in rescue of nuclear localization and TSS formation. It would be of 
interest to determine if this rescue of proper localization also resulted in a rescue of the 
transcriptional trans-activation activity of these Tax constructs. 
We can use these tools to examine the link between Tax oligomerization and 
function. A useful tool for these studies is the inducible dimerization construct. In our 
studies we chose the Tax deletion mutant STax(d99-150)GFP for addition of the 
inducible dimerizer domain. We were able to show that induced dimerization of this 
construct resulted in an increase in its nuclear accumulation. Just as for the NLS and 
TSTS mutants, future studies with this construct will analyze the effect of induced 
dimerization of this mutant on its fr*ara,-activation capabilities. Also, we have constructed 
three other Tax dimerization domain mutants that are excluded from the nucleus. Each of 
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these constructs will have the dimerizer domain added to see if induced dimerization of 
these mutants results in a similar rescue of nuclear accumulation as for STax(d99-150)-
Fv-GFP. ARIAD Pharmaceutical, who created the inducible homodimerization system 
employed in these studies, has also developed a system to induce heterodimerization. 
We could introduce different dimerizing domains into the dimerization deficient mutants. 
We could then determine whether induced heterodimerization between constructs 
missing different dimerization subdomains is also able to restore nuclear localization. 
A particularly interesting finding in our study was the cytoplasmic localization of 
STax(d254-289)GFP. This construct is deleted in a region that only overlaps the 
previously identified Tax dimerization domain by two residues (101), and yet this 
deletion mutant displays a similar cytoplasmic localization and ability to be rescued by 
wildtype Tax as the dimerization subdomain mutants. This mutant did display a slightly 
stronger ability to dimerize with wildtype Tax than the dimerization mutants as indicated 
in Figure 9. This construct is also deleted in the region containing the two lysine residues 
sumoylated and ubiquitylated affecting the localization of Tax. Additional studies will 
focus on determining whether this construct represents an additional region required for 
Tax dimerization or if the cytoplasmic localization is due to the loss of another Tax 
function such as the ability to be ubiquitylated or sumoylated. 
The most exciting area for future studies is the relationship between Tax and 
RNF4. We have shown that RNF4 is capable of ubiquitinylating Tax in vitro, and 
overexpression of RNF4 results in a relocalization of Tax to the cytoplasm. Since Tax is a 
predominantly nuclear protein, we would expect that Tax-expressing cells might repress 
the expression of RNF4. There are several cell lines that are HTLV-1 infected and 
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immortalized or transformed and express varying amounts of Tax. It would be of interest 
to examine the levels of RNF4 transcription by quantitative real time polymerase chain 
reaction (RT-PCR) in these cells and compare RNF4 mRNA levels to non-Tax-
expressing parental lines. Recent studies by Gatza et al demonstrated that UV irradiation 
of Tax-expressing cells resulted in the ubiquitination and nuclear egress of Tax (90). We 
will use RT-PCR and irnrnunoblot analysis to look at transcription and expression of 
RNF4 in response to UV irradiation to see if the ubiquitination of Tax following DNA 
damage may be mediated through RNF4. Also, by identifiying Tax as the target for 
RNF4 and characterizing this interaction, we may be able to begin to define other cellular 
proteins that are ubiquitylated by RNF4 and affect cellular functions. 
The interaction of Tax with RNF4 is only half of the Tax ubiquitylation/ 
sumoylation story. Although in this study we have identified an ubiquitin ligase that may 
modify Tax by ubiquitylation, no cellular protein has been shown to be responsible for 
the sumoylation of Tax to date. Previously, our lab has performed liquid chromotography 
-tandem mass spectrometry (LC-MS/MS) analysis of Tax-binding proteins in which we 
identified a cellular SUMO ligase, RanBP2. This is a nucleoporin with SUMO ligase 
activity that is localized to the cytoplasmic filaments of the nuclear pore complex (223). 
The interaction between Tax and RanBP2 may provide the missing piece to the 
sumoylation/ubiquitylation story for Tax. We propose a model for the regulation of Tax 
nucleocytoplasmic shuttling in which RanBP2 sumoylates Tax dimers (with NES 
masked) in the cytoplasm, leading to nuclear localization via its NLS and TSS targeting 
via the TSTS. RNF4 then targets sumoylated Tax for ubiquitylation, exposing the Tax 
NES and resulting in the nuclear export of Tax. Future studies will focus on efforts to 
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examine the nature of the interaction between RanBP2, RNF4 and Tax and on finding 
assays to test the validity of our model. 
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APPENDIX A 
Experimental Procedure for in vitro Ubiquitylation Assay 
RNF4 and TAX were expressed as MBP fusions in BL21 StarTM (DE3) cells 
containing plasmid pRIL, which expresses several rare-codon tRNAs (a gift from 
Sean Prigge, JHSOM, MD). Proteins were affinity purified on an amylose resin 
(New England Biolabs). Ubiquitylation Assays were performed using reagents purchased 
from BIOMOL using manufacturer's instructions (Biomol #UW9920). Briefly, 2uM 
purified RNF4 and lOuM TAX fusion proteins were pre-incubated at RT for 15 minutes 
and then added into a ubiquitylation reaction containing El, E2 (Mms2/Ubcl3), ATP, 
reaction buffer, and Biotin-ubiquitin. Controls were set up as indicated omitting 
ATP (lane 1), E2 (Mms2/Ubcl3 - lane 2)), E3 (RNF4-MBP - lane 3) from the 
reactions or adding ImM MBP (lane 5 and 7). Additionally, complete reactions 
(ALL) containing purified SUMO was included (lane 6 and 7). Ubiquitylation reactions 
were allowed to proceed for 60min at 37°C and terminated using reducing SDS-PAGE 
sample buffer. Proteins were separated on 8-12% SDS-PAGE gels, transferred to PVDF 
membranes, and visualized using anti TAX antibodies and ECL (Pierce 
34080). Ubiquitylated Tax-MBP proteins are visible as high-molecular weight adducts 
extending from ~80-250kDa (lane 4 and 5). 
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